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1. INTRODUCTION 
(Panchal DR., et al., 2012) 
 
Recently, controlled and sustained drug delivery has become the standard in 
modern Pharmaceutical design and an intensive research have been undertaken in 
achieving much better drug product effectiveness, reliability and safety. Over the past 
30 years greater attention has been focused on development of controlled and 
sustained drug delivery systems.  
The most desirable and convenient method of drug administration is the oral 
route because of their ease of administration. However, in many instances oral 
administration is not desirable when the drug undergoes significant degradation via 
first pass effect in liver. Hence, lack of systemic absorption through the 
gastrointestinal tract led to research on alternate routes of drug delivery such as 
parenteral, intramuscular, subcutaneous, intranasal, transdermal etc.  
Intranasal (IN) administration is a needle free and hence an ideal alternative to 
the parenteral route for systemic drug delivery. Nasal mucosa consists of a rich 
vasculature and a highly permeable structure for systemic absorption. Drug 
administration through the nasal cavity is easy and convenient. Avoidance of first pass 
metabolism is the main advantage of nasal route of drug delivery. 
Intranasal delivery is non-invasive, essentially painless, does not require sterile 
preparation and it is easily and readily administered by the patient or a physician for 
e.g. in an emergency setting. Given these positive attributes, it is logical to consider 
intranasal administration extending the life or improving the profile of an existing 
drug. 
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1.1.  Mucoadhesive Drug Delivery System:         
                                                         (Flavia Chiva Carvalho, et al., 2010) 
Bioadhesive is the term that describes the adhesion of a polymer to a biological 
substrate. More specifically, when adhesion is restricted to the mucous layer lining of 
the mucosal surface it is termed as mucoadhesion.  
Mucoadhesive controlled release devices can improve the effectiveness of a 
drug by maintaining the drug concentration between the effective and toxic levels, 
inhibiting the dilution of drug in the body fluids, and allowing targeting and 
localization of a drug at a specific site. 
Mucoadhesion also increases the intimacy and duration of contact between a 
drug containing polymer and a mucous surface. The combined effects of the direct 
drug absorption and decrease in excretion rate (due to prolonged residence time) allow 
for an increased bioavailability of the drug with a smaller dosage and less frequent 
administration.  
Bioadhesive system can prevent the first pass metabolism of certain protein 
drugs by the liver through the introduction of the drug via route bypassing the 
digestive tract. Drugs that are absorbed through the mucosal lining of tissues can enter 
directly into the blood stream and prevented from enzymatic degradation in the GIT. 
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1.1.1. Fundamentals of  Bioadhesion: 
        Development of an adhesive bond between a polymer and biological 
membrane or its coating can be visualized as a two step process: 
 Initial contact between the two surfaces. 
 Formation of secondary bonds due to non-covalent interaction. 
This process of bond formation attributed to surface (or surface coat) of the 
biological membrane surface of the adhesive and the interfacial layer between the two 
surfaces. Molecular events that take place in the interfacial layer depend on the 
properties of the polymer and membrane. 
1.1.2. NEED OF MUCOADHESIVE DELIVERY  
As compared to oral controlled release systems, mucoadhesive delivery system 
have several advantages by virtue of prolongation of residence time, drug 
targeting, intimate contact between dosage form and the absorptive mucosa. In 
addition, mucoadhesive dosage forms have been used to target local disorders at 
the mucosal surface to reduce dose and to minimize the side effects. Mucoadhesive 
formulations use polymers as the adhesive component. These polymers are often 
water soluble and when used in a dry form, they attract water from the mucosal 
surface and this water transfer leads to a strong interaction further increasing the 
retention time over the mucosal surfaces and leads to adhesive interactions. 
Prolonged contact time of a drug with a body tissue through the use of a 
bioadhesive polymer can significantly improve the performance of many drugs. 
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Fig 1.1: Diagramatic representation of mucoadhesive drug delivery system 
1.1.3.  Mechanism of Mucoadhesion: 
The mucoadhesive must spread over the substrate to initiate close 
contact and increase surface contact, promoting the diffusion of its chains 
within the mucus. Attraction and repulsion forces arise and, for a 
mucoadhesive to be successful, the attraction forces must dominate. Each step 
can be facilitated by the nature of the dosage form and how it is administered. 
For example, a partially hydrated polymer can be adsorbed by the substrate 
because of the attraction by the surface water. 
      As stated, mucoadhesion is the attachement of the drug along with a 
suitable carrier to the mucous membrane. Mucoadhesion is a complex 
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phenomenon which involves wetting, adsorption and interpenetration of 
polymer chains. Mucoadhesion has the following mechanism, 
1. Intimate contact between a bioadhesive and a membrane (wetting or 
swelling phenomenon). 
2. Penetration of the bioadhesive into the tissue or into the surface of the 
mucous membrane (interpenetration) 
The mechanism of mucoadhesion is generally divided in two steps, 
 The contact stage  
 The contact stage 
The contact stage: 
The contact stage is characterized by the contact between the mucoadhesive 
and the mucous membrane, with spreading and swelling of the formulation, initiating 
its deep contact with the mucus layer. In some cases, such as for ocular or vaginal 
formulations, the delivery system is mechanically attached over the membrane. In 
other cases, the deposition is promoted by the aerodynamics of the organ to which the 
system is administered, such as for the nasal route. On the other hand, in the 
gastrointestinal tract direct formulation attachment over the mucous membrane is not 
feasible. Peristaltic motions can contribute to this contact, but there is little evidence in 
the literature showing appropriate adhesion. Additionally, an undesirable adhesion in 
the esophagus can occur. In these cases, mucoadhesion can be explained by peristalsis, 
the motion of organic fluids in the organ cavity, or by Brownian motion. If the particle 
approaches the mucous surface, it will come into contact with repulsive forces 
Nasal In situ gel of Rizatriptan Benzoate                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 6 
(osmotic pressure, electrostatic repulsion, etc.) and attractive forces (van der Waals 
forces and electrostatic attraction). Therefore, the particle must overcome this 
repulsive barrier). 
The consolidation step: 
In the consolidation step (Figure 1.2), the mucoadhesive materials are activated 
by the presence of moisture. Moisture plasticizes the system, allowing the mucoadhe-
sive molecules to break free and to link up by weak van der Waals and hydrogen 
bonds.  
Essentially, there are two theories explaining the consolidation step: the 
diffusion theory and the dehydration theory. 
According to diffusion theory, the mucoadhesive molecules and the 
glycoprotein of the mucus mutually interact by means of interpenetration of their 
chains and the building of secondary bonds. For this to take place the mucoadhesive 
device has features favoring both chemical and mechanical interactions. For example, 
molecules with hydrogen bonds building groups (–OH, –COOH), with an anionic 
surface charge, high molecular weight, flexible chains and surface-active properties, 
which induct its spread throughout the mucus layer, can present mucoadhesive 
properties. 
Nasal In situ gel of Rizatriptan Benzoate                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 7 
 
Fig 1.2: Diagramatic representation of two steps of the mucoadhesion process.            
According to dehydration theory, materials that are able to readily gelify in an 
aqueous environment, when placed in contact with the mucus can cause its 
dehydration due to the difference of osmotic pressure. The difference in concentration 
gradient draws the water into the formulation until the osmotic balance is reached. 
This process leads to the mixture of formulation and mucus and can thus increase 
contact time with the mucous membrane. Therefore, it is the water motion that leads to 
the consolidation of the adhesive bond, and not the interpenetration of macromolecular 
chains. However, the dehydration theory is not applicable for solid formulations or 
highly hydrated forms. 
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  Fig 1.3: A Schematic diagram of dehydration theory of  mucoadhesion 
 
Mucoadhesion Theories:                                 ( Flavia Chiva Carvalho1., et al., 2010) 
 
Although the chemical and physical basis of mucoadhesion are not yet well 
understood, there are six classical theories adapted from studies on the performance of 
several materials and polymer-polymer adhesion which explain the phenomenon. 
 Electronic theory  
Electronic theory is based on the premise that both mucoadhesive and 
biological materials possess opposing electrical charges. Thus, when both materials 
come into contact, they transfer electrons leading to the building of a double electronic 
layer at the interface, where the attractive forces within this electronic double layer 
determines the mucoadhesive strength. 
 Adsorption theory 
  
According to the adsorption theory, the mucoadhesive device adheres to the 
mucus by secondary chemical interactions, such as in van der Waals and hydrogen 
bonds, electrostatic attraction or hydrophobic interactions. For example, hydrogen 
bonds are the prevalent interfacial forces in polymers containing carboxyl groups. 
Such forces have been considered the most important in the adhesive interaction 
Nasal In situ gel of Rizatriptan Benzoate                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 9 
phenomenon because, although they are individually weak, a great number of 
interactions can result in an intense global adhesion . 
 Wetting theory 
  
The wetting theory applies to liquid systems which present affinity to the 
surface in order to spread over it. This affinity can be found by using measuring 
techniques such as the contact angle. The general rule states that the lower the contact 
angle then the greater the affinity (Figure 1.4). The contact angle should be equal or 
close to zero to provide adequate spreadability. 
 
Fig 1.4: Schematic diagram showing influence of contact angle between device and 
mucous membrane on bioadhesion. 
The spreadability coefficient, SAB, can be calculated from the difference between 
the surface energies γB and γA and the interfacial energy γAB, as indicated in equation 
(1). 
S AB = γ B – γ A- γ AB                                                                                                                             (1) 
 
 The greater the individual surface energy of mucus and device in relation to the 
interfacial energy, the greater the adhesion work, WA, i.e. the greater the energy  
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needed to separate the two phases.  
WA = γ A+ γ B – AB                                                                                                                       (2) 
 Diffusion theory  
Diffusion theory describes the interpenetration of both polymer and mucin 
chains to a sufficient depth to create a semi-permanent adhesive bond (Figure 4). It is 
believed that the adhesion force increases with the degree of penetration of the 
polymer chains . This penetration rate depends on the diffusion coefficient, flexibility 
and nature of the mucoadhesive chains, mobility and contact time. According to the 
literature, the depth of interpenetration required to produce an efficient bioadhesive 
bond lies in the range 0.2-0.5 μm. This interpenetration depth of polymer and mucin 
chains can be estimated by equation 3: 
l = (tDb)
 ½                                                                                                                                                   (3)   
where t is the contact time, and Db is the diffusion coefficient of the mucoadhesive 
material in the mucus. The adhesion strength for a polymer is reached when the depth 
of penetration is approximately equivalent to the polymer chain size. 
In order for diffusion to occur, it is important that the components involved have 
good mutual solubility, that is, both the bioadhesive and the mucus have similar 
chemical structures. The greater the structural similarity, the better the mucoadhesive 
bond. 
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Fig 1.5: A Schematic diagram of Secondary interactions resulting from 
interdiffusion of polymer chains of bioadhesive device and of mucus 
 Fracture theory  
This is perhaps the most-used theory in studies on the mechanical measurement 
of mucoadhesion. It analyses the force required to separate two surfaces after adhesion 
is established. This force, sm, is frequently calculated in tests of resistance to rupture 
by the ratio of the maximal detachment force, Fm, and the total surface area, A0, 
involved in the adhesive interaction (equation 4): 
S m = Fm/Ao                                                                                                                                          (4) 
In a single component uniform system, the fracture force, sj, which is 
equivalent to the maximal rupture tensile strength, sm, is proportional to the fracture 
energy (gc), for Young’s module (E) and to the critical breaking length (c) for the 
fracture site, as described in equation 5: 
Sf  ~ [gcE/c]
1/2
                                                                                                  (5) 
Fracture energy (gc) can be obtained from the reversible adhesion work, Wr 
(energy required to produce new fractured surfaces), and the irreversible adhesion 
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work, Wi (work of plastic deformation provoked by the removal of a proof tip until the 
disruption of the adhesive bond), and both values are expressed as units of fracture 
surface (Af). 
gc =  Wr +W1                                                                                                                                             (6) 
The elastic module of the system (E) is related to the stress (s) and to the shear 
(e) by Hooke’s law:  
   E = [σ/ε] ε ->0 = [F/A0/ΔI/l0] Δl ->0                                                                                                       (7) 
In equation 7, the stress is the ratio between force (F) and area (A0), and shear is 
given by the ratio between the variation of system thickness (Dl) and the original 
thickness (l0).  
A criticism of this analysis is that the system under investigation must have 
known physical dimensions and should be constituted by a single and uniform 
material. In virtue of this, the relationship obtained cannot be applied to analyze the 
fracture site of a multiple component bioadhesive. In this case, the equation should be 
expanded to accommodate elastic dimensions and modules for each component. 
Besides, it must be considered that a failure of adhesion will occur at the bioadhesive 
interface. However, it has been demonstrated that the rupture rarely occurs at the 
surface, but near it or at the weakest point, which can be the interface itself, the mucus 
layer or the hydrated region of the mucus, as illustrated in Figure 1.5. Since the 
fracture theory is concerned only with the force required to separate the parts, it does 
not take into account the interpenetration or diffusion of polymer chains. 
Consequently, it is appropriate for use in the calculations for rigid or semi-rigid 
bioadhesive materials, in which the polymer chains do not penetrate into the mucus 
layer 
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 Mechanical theory  
Mechanical theory considers adhesion to be due to the filling of the irregularities 
on a rough surface by a mucoadhesive liquid. Moreover, such roughness increases the 
interfacial area available to interactions thereby aiding dissipating energy and can be 
considered the most important phenomenon of the process.  
It is unlikely that the mucoadhesion process is the same for all cases and 
therefore it cannot be described by a single theory. In fact, all theories are relevant to 
identify the important process variables. 
The mechanisms governing mucoadhesion are also determined by the intrinsic 
properties of the formulation and by the environment in which it is applied . Intrinsic 
factors of the polymer are related to its molecular weight, concentration and chain 
flexibility. For linear polymers, mucoadhesion increases with molecular weight, but 
the same relationship does not hold for non-linear polymers. It has been shown that 
more concentrated mucoadhesive dispersions are retained on the mucous membrane 
for longer periods, as in the case of systems formed by in situ gelification. After 
application, such systems spread easily, since they present rheological properties of a 
liquid, but gelify as they come into contact the absorption site, thus preventing their 
rapid removal. Chain flexibility is critical to consolidate the interpenetration between 
formulation and mucus. 
 Environment related factors include pH, initial contact time, swelling and 
physiological variations. The pH can influence the formation of ionizable groups in 
polymers as well as the formation of charges on the mucus surface. Contact time 
between mucoadhesive and mucus layer determines the extent of chain 
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interpenetration. Super-hydration of the system can lead to build up of mucilage 
without adhesion. The thickness of the mucus layer can vary from 50 to 450 μm in the 
stomach  to less than 1μm in the oral cavity. Other physiological variations can also 
occur with diseases.  
None of these mechanisms or theories alone can explain the mucoadhesion which 
occurs in an array of different situations. However, the understanding of these 
mechanisms in each instance can help toward the development of new mucoadhesive 
products . 
1.1.3. Common Sites of Application for Mucoadhesive Drug Delivery Platform: 
Mucoadhesive formulations have been widely used for their targeted and 
controlled release delivery to many mucosal membrane based organelles. Such 
formulations may deliver active ingredient for local systemic effect, while 
bioavailability limiting effects such as enzymatic or hepatic degradation can be 
avoided or minimized. 
 In each case of these mucosal routes, mucus characteristics and functions are 
different. By this definition, the mucosal routes for drug delivery are: 
 Buccal drug delivery system 
 Ophthalmic drug delivery system 
 Vaginal drug delivery system  
 Nasal drug delivery system 
 
 Buccal drug delivery  
The buccal cavity offers many advantages for drug delivery application. The 
most significant advantage offered is high accessibility and low enzymatic activity. 
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Additionally, buccal drug delivery can be promptly terminated in cases of toxicity 
through the removal of dosage form thereby offering a safe and easy method of drug 
utilization. Various polymers such as sodium carboxymethylcellulose, 
hydroxypropylcellulose and polycarbophil are used for delivery of peptides, protein 
and polysaccharides by this routes have been examined.
 
Although gel and ointments 
are the most patient convenient tablets, patches and films have also been examined. 
Furthermore buccal drug delivery is associated with high patient compliance, low 
levels of irritation and offers significant ease of administration. 
Ophthalmic drug delivery 
 The delivery of therapeutic agents to the eye may be achieved using various 
types of dosage forms including liquid drops, gels, ointments and solid ocular inserts 
(both degradable and nondegradable). Another interesting delivery system is in situ 
gelling polymer that undergoes a phase transition after application. Mucoadhesive 
polymers would be expected only to attach to conjunctival mucus in vivo. Additionally 
limited bioavailability has been experienced in vivo for carbomer and polycarbophil,
 
as a result of the high swelling capacity of such polymers in the neutral pH 
environment of the eye. Maintenance of a low viscosity in such systems through pH 
regulation in the range 4–5 is not acceptable as it may result in patient unease and mild 
lacrimation, both of which will have an effect on treatment success. User acceptance 
and compliance may subsequently be limited by physical and psychological barriers 
surrounding such dosage forms. 
Vaginal drug delivery systems 
 Vaginal drug delivery offers many advantages; the avoidance of hepatic first-
pass metabolism, a decrease in hepatic side effects and avoidance of pain, tissue 
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damage, and infection commonly observed for parenteral drug delivery routes of 
administration. While the vagina provides a promising site for systemic drug delivery 
because of its large surface area, rich blood supply and high permeability, poor 
retention due to the self-cleansing action of the vaginal tract is often problematic. 
However, residence times within the vagina tend to be much higher than at other 
absorption sites such as the rectum or intestinal mucosa. Another important 
consideration is the change in the vaginal membrane during the menstrual cycle and 
post-menopausal period. Typical bioadhesive polymers that have been in vaginal 
formulations include polycarbophil, hydroxypropylcellulose and polyacrylic acid. 
Nasal drug delivery 
 One of the key advantages provided by intranasal drug delivery is that the 
nasal cavity provides a large highly vascularised surface area through which first-pass 
metabolism can be avoided, as blood is drained directly from the nose into the 
systemic circulation. Successful nasal delivery has been obtained using solutions, 
powders, gels and microparticles. The most commonly employed intranasal active 
ingredient are solutions containing sympathomimetic vasoconstrictors for immediate 
relief of nasal congestion. Local delivery of these alpha adrenergic stimulators is of 
particular benefit to patients with high blood pressure (or those at heightened risk of 
cardiovascular incident), as vasoconstriction will occur to the greatest degree within 
the nose. In addition to local effects, the intranasal route of drug administration has 
also been used to achieve a distal systemic effect. One such example is the intranasal 
delivery of the peptide desmopressin that exerts its action on the kidneys, mimicking 
the action of antidiuretic hormone, used mainly in Diabetes insipidus. 
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Table 1.1: Comparative properties of gastrointestinal, dermal and transmucosal drug 
administration: 
 + Poor, + + Good, + + + Excellent 
1.2.  Nasal Drug Delivery System: 
The administration of drugs via nose is not a novel approach for drug delivery. 
In ancient days, nasal drug delivery was used for the systemic administration of 
psychotherapeutic compounds and other similar substances. But in modern 
pharmaceutics, nasal drug delivery is considered as a route of choice for local effect 
rather than systemic effect. Delivery of drugs via nose for maintenance therapy of 
nasal allergy, sinusitis, nasal congestion, and nasal infections.  
In recent years, research has established that the nasal route is a safe and 
acceptable alternative to the parenteral administration of drugs. The nasal route has 
also been found to be useful in targeting drugs to the central nervous system (CNS). 
 
Gastrointestinal Dermal Nasal 
Oral 
mucosal 
Vaginal 
Accessibility + +++ ++ ++ + 
Surface area +++ +++ + ++ +++ 
Surface 
Enviornment 
+ ++ ++ +++ + 
Permiability +++ + +++ ++ +++ 
Reactivity ++ ++ + +++ ++ 
Vascular 
Drainage 
+++ + +++ ++ +++ 
First pass 
clearance 
+ +++ +++ +++ + 
Patient 
acceptability 
++ +++ ++ +++ +++ 
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The greater permeability of nasal mucosa with large surface area affords a rapid onset 
of therapeutic effect. The low metabolic environment of nose has potential to 
overcome the limitations of oral route and duplicate the benefit of intravenous 
administration. 
1.2.1.  Anatomy and Physiology of Nose:   (Amol., et al., 2011) 
       The nose is divided into two nasal cavities via the septum. The volume of 
nasal cavity is approximately15 ml with a surface area of around 150 cm². 
 
Fig 1.6: A Schematic representation of a sagittal section of human nasal cavity  
Schematic representation of a sagittal section of human nasal cavity showing the 
nasal vestibule , Atrium , respiratory region: inferior turbinate, middle turbinate and 
the superior turbinate,  the olfactory region  and  nasopharynx . 
 
 The Vestibule: 
It consists of the region just inside the nostrils (~0.6 cm²). The nasal vestibule is 
covered with stratified sqamous epithelium. This gradually changes in the posterior 
into a pseudostratified columnar epithelium that covers the respiratory epithelium. 
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 The Respiratory Region: 
  It contains three nasal turbinates, the superior, middle and inferior which 
project from the lateral wall of each half of the nasal cavity. The presence of these 
turbinates creates a turbulent airflow through the nasal passages, which ensures better 
contact between the inhaled air and the mucosal surface. The respiratory epithelial 
cells are covered with cilia and microvilli, which increase the surface area available for 
the absorption of drugs. 
 The Olfactory Region: 
 It is situated in the roof of the nasal cavity (15cm²). The olfactory tissue is often 
yellow in colour, in contrast to the surrounding pink tissue. 
 
  
 
 
 
 
         
 
 
               Fig 1.7: A Schematic diagram of olfactory epithelium. 
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Table 1.2: Structural Feature of Different Sections of Nasal Cavity and their      
Relative Impact on Permeability. 
 
 
Region Structural Features Structural Features 
Nasal vestibule  Nasal hairs (vibrissae) Epithelial 
cells are stratified, squamous and 
keratinized Sebaceous glands present 
Least permeable because of the 
presence of Keratinized cells 
Atrium  Transepithelial region Stratified 
squamouscells present anteriorly and 
pseudo stratified cells with microvilli 
present posteriorly 
Less permeable as it has small surface 
area and stratified cells are present 
anteriorly 
Respiratory region 
(inferior turbinate 
middle turbinate 
superior turbinate) 
 Pseudo stratified ciliated columnar 
cells with microvilli (300 per 
cell),large surface area 
 Receives maximum nasal secretions 
becauseof the presence of 
seromucus glands, nasolacrimal 
duct and goblet cells 
 Richly supplied with blood for 
heating and humidification of 
inspired air, presence of paranasal 
sinuses 
Most permeable regionbecause of 
large surfacearea and rich vasculature 
Olfactory region  Specialized ciliated olfactory nerve 
cells for smell perception 
 Receives ophthalmic and maxillary 
divisions of trigeminal nerve 
Direct access to cerebrospinal fluid 
Nasopharynx  Upper part contains ciliated cells 
and lower part contains squamous 
epithelium 
Receives nasal cavity 
Drainage 
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1.2.2. Advantages of Nasal Drug Delivery System:   (Rahishuddin., et al., 2011) 
 Drug degradation that is observed in the gastrointestinal tract is absent.  
 Hepatic first pass metabolism is avoided.  
 Rapid drug absorption and quick onset of action can be achieved.  
 The bioavailability of larger drug molecules can be improved by means of 
absorption enhancer or other approach.  
 The nasal bioavailability for smaller drug molecules is good.  
 Drugs that are orally not absorbed can be delivered to the systemic circulation 
by nasal drug delivery. 
  Drugs possessing poor stability in G.I.T. fluids are given by nasal route.  
 Polar compounds exhibiting poor oral absorption may be particularly suited for 
this route of delivery.  
 Convenient for those on long term therapy, when compared with parenteral 
medication. 
1.2.3. Limitations of Nasal Drug Delivery System: 
 Absorption surface area is less when compared to GIT. 
 Once the drug administered cannot be removed. 
 Nasal irritation 
1.2.4. Mechanism of Nasal Absorption:     (Rahisuddin., et al., 2010) 
           The absorbed drugs from the nasal cavity must pass through the mucus layer, it 
is the first step in absorption. Small, unchanged drugs easily pass through this layer 
but large, charged drugs are difficult to cross it. The principle protein of the mucus is 
mucin, it has the tendency to bind to the solutes, hindering diffusion. Additionally, 
structural changes in the mucus layer are possible as a result of environmental changes 
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(i.e. pH, temperature, etc.). So many absorption mechanisms were established earlier 
but only two mechanisms have been predominantly used, such as: 
           First mechanism 
It involves an aqueous route of transport, which is also known as the 
paracellular route but slow and passive. There is an inverse log-log correlation 
between intranasal absorption and the molecular weight of water-soluble 
compounds. The molecular weight greater than 1000 Daltons having drugs shows 
poor bioavailability 
            Second mechanism 
 It involves transport through a lipoidal route and it is also known as the 
transcellular process. It is responsible for the transport of lipophilic drugs that show a 
rate dependency on their lipophilicity. Drug also cross cell membranes by an active 
transport route via carrier-mediated means or transport through the opening of tight 
junctions . 
For examples: Chitosan, a natural biopolymer from shellfish, opens tight 
junctions between epithelial cells to facilitate drug transport. 
 
 
 
 
 
                                      Figure 
1.8: Cell types of the nasal epithelium  
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 The cell type of nasal epithelium showing ciliated cell (A), non-ciliated 
cell(B), goblet cells(C), gel mucus layer (D), sol layer (E), basal cell (F) and basement 
membrane (G). 
1.2.5. Barriers to Nasal Absorption:  ( Swamya N.G.N, et al., 2012) 
Nasal drug delivery system is considered has a profitable route for the 
formulation scientist because it has easy and simple formulation strategies. 
Intranasally administered drug products therapeutic efficacy and toxicities are 
influenced by number of factors. 
Following factors are the barriers to the absorption of drugs through nasal 
cavity. 
 Low bioavailability 
Bioavailability of polar drugs is generally low about 10% for low molecular 
weight drugs and not above 1% for peptides such as calcitonin and insuin.The most 
important factor limiting the nasal absorption of polar drugs and especially large 
molecular weight polar drugs such as peptides and proteins is the low membrane 
permeability. Larger peptides and proteins are able to pass the nasal membrane using 
an endocytotic transport process but only in low amounts. 
 Mucociliary clearance 
The drugs administered by nasal route are subject to fast clearance from the 
nasal cavity owing to mucociliary clearance. As a result of this, it leads to decreased 
transport of drugs across the nasal mucosa. This is especially the case, when the drug 
is not absorbed rapidly enough across the nasal mucosa. It has been shown that for 
both liquid and powder formulations, which are not bioadhesive, the half-life for 
clearance is of the order of 15-30 min. The use of bioadhesive excipients in the 
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formulations is an approach to overcome the rapid mucociliary clearance. The 
clearance may also be reduced by depositing the formulation in the anterior and less 
ciliated part of the nasal cavity thus leading to improved absorption. 
 Enzymatic degradation 
Another contributing, but often less considered factor to the low bioavailability 
of peptides and proteins across the nasal mucosa is the possibility of an enzymatic 
degradation of the molecule in the lumen of the nasal cavity or during passage through 
the epithelial barrier. Both these sites contain exopeptidases such as mono and diamino 
peptidases that can cleave peptides at their N and C termini and endopeptidases such 
as serine and cysteine, which can attack internal peptide bonds . 
The use of enzyme inhibitors and/or saturation of enzymes may be the approaches to 
overcome this barrier. 
1.2.6. Factors  Influencing Nasal Drug Absorption:    (Panchal D. R., et al., 2012) 
Several factors affect the systemic bioavailability of drugs which are 
administered through the nasal route. The factors influencing nasal drug absorption are 
described as follows. 
 Physiochemical properties of drug. 
 Molecular size.  
 Lipophilic-hydrophilic balance.  
 Enzymatic degradation in nasal cavity.  
  Nasal Effect  
 Membrane permeability.  
 Environmental pH  
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 Mucociliary clearance  
 Cold, rhinitis.  
  Delivery Effect  
 Formulation (Concentration, pH, osmolarity)  
 Delivery effects  
 Drugs distribution and deposition.  
 Viscosity  
 Physiochemical properties of drug  
 Molecular size  
The molecular size of the drug influence absorption of the drug through the 
nasal route. The lipophilic drugs have direct relationship between the MW and drug 
permeation whereas water- soluble compounds depict an inverse relationship. The rate 
of permeation is highly sensitive to molecular size for compounds with MW ≥ 300 
Daltons. 
 Lipophilic-hydrophilic balance  
The hydrophilic and lipophilic nature of the drug also affects the process of 
absorption. By increasing lipophilicity, the permeation of the compound normally 
increases through nasal mucosa. Although the nasal mucosa was found to have some 
hydrophilic character, it appears that these mucosae are primarily lipophilic in nature 
and the lipid domain plays an important role in the barrier function of these 
membranes. Lipophilic drugs like naloxone, buprenorphine, testosterone and 17a-
ethinyl- oestradiol are almost completely absorbed when administered intranasal route 
 Enzymatic degradation in nasal cavity  
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In case of peptides and proteins are having low bioavailability across the nasal 
cavity, so these drugs may have possibility to undergo enzymatic degradation of the 
drug molecule in the lumen of the nasal cavity or during passage through the epithelial 
barrier. These both sites are having exopeptidases and endopeptidases, exopeptidases 
are monoaminopeptidases and diaminopeptidases. These are having capability to 
cleave peptides at their N and C termini and endopeptidases such as serine and 
cysteine, which can attack internal peptide bonds. 
 Nasal effect factors  
 Membrane permeability  
Nasal membrane permeability is the most important factor, which affect the 
absorption of the drug through the nasal route. The water soluble drugs and 
particularly large molecular weight drugs like peptides and proteins are having the low 
membrane permeability. So the compounds like peptides and proteins are mainly 
absorbed through the endocytotic transport process in low amounts. Water-soluble 
high molecular weight drugs cross the nasal mucosa mainly by passive diffusion 
through the aqueous pores (i.e. tight junctions). 
 Environmental pH  
The environmental pH plays an important role in the efficiency of nasal drug 
absorption. Small water-soluble compounds such as benzoic acid, salicylic acid, and 
alkaloid acid show that their nasal absorption in rat occurred to the greatest extent at 
those pH values where these compounds are in the nonionised form. However, at pH 
values where these compounds are partially ionized, substantial absorption was found. 
This means that the nonionised lipophilic form crosses the nasal epithelial barrier via 
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transcellular route, whereas the more lipophilic ionized form passes through the 
aqueous paracellular route. 
 Mucociliary clearance  
Mucociliary clearance is a one of the functions of the upper respiratory tract is 
to prevent noxious substances (allergens, bacteria, viruses, toxins etc.) from reaching 
the lungs. When such materials adhere to, or dissolve in, the mucus lining of the nasal 
cavity, they are transported towards the nasopharynx for eventual discharge into the 
gastrointestinal tract . Clearance of this mucus and the adsorbed/dissolved substances 
into the GIT is called the MCC. This clearance mechanism influence the absorption 
process due to the dissolved drugs in the nasal cavity are discharge by the both the 
mucus and the cilia, which is the motor of the MCC and the mucus transport rate is 6 
mm/min. It is of utmost importance that the MCC is not impaired in order to prevent 
lower respiratory tract infections. 
 Cold, rhinitis  
Rhinitis is a most frequently associated common disease, it influence the 
bioavailability of the drug. It is mainly classified into allergic rhinitis and common, the 
symptoms are hyper secretion, itching and sneezing mainly caused by the viruses, 
bacteria or irritants. Allergic rhinitis is the allergic airway disease, which affects 10% 
of population. It is caused by chronic or acute inflammation of the mucous membrane 
of the nose. These conditions affect the absorption of drug through the mucus 
membrane due the inflammation. 
 Delivery effect factors  
Factors that affect the delivery of drug across nasal mucosa such as surfactants, 
dose pH, osmolarity, viscosity, particle size and nasal  
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clearance, drug structure can be used to advantage to improve absorption.  
 Formulation (Concentration, pH, Osmolarity) 
The pH of the formulation and nasal surface, can affect a drugs permeation. To 
avoid nasal irritation, the pH of the nasal formulation should be adjusted to 4.5-6.5 
because lysozyme is found in nasal secretions, which is responsible for destroyin 
certain bacteria at acidic pH. Under alkaline conditions, lysozyme is inactivated and 
the tissue is susceptible to microbial infection. In addition to avoiding irritation, it 
results in obtaining efficient drug permeation and prevents the growth of bacteria. 
Concentration gradient plays very important role in the absorption /permeation 
process of drug through the nasal membrane due to nasal mucosal damage. Examples 
for this are nasal absorption of L-Tyrosine was shown to increase with drug 
concentration in nasal perfusion experiments. Another is absorption of salicylic acid 
was found to decline with concentration. This decline is likely due to nasal mucosa 
damage by the permanent. 
The osmolarity of the dosage form affects the nasal absorption of the drug; it 
was studied in the rats by using model drug. The sodium chloride concentration of the 
formulation affects the nasal absorption. The maximum absorption was achieved by 
0.462 M sodium chloride concentration; the higher concentration not only causes 
increased bioavailability but also leads to the toxicity to the nasal epithelium. 
 Drugs distribution and deposition  
The drug distribution in the nasal cavity is one of the important factors, which 
affect the efficiency of nasal absorption. The mode of drug administration could effect 
the distribution of drug in nasal cavity, which in turn will determine the absorption 
efficiency of a drug. The absorption and bioavailability of the nasal dosage forms 
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mainly depends on the site of disposition. The anterior portion of the nose provides a 
prolonged nasal residential time for disposition of formulation, it enhances the 
absorption of the drug. And the posterior chamber of nasal cavity will use for the 
deposition of dosage form, it is eliminated by the mucociliary clearance process and 
hence shows low bioavailability. The site of disposition and distribution of the dosage 
forms are mainly depends on delivery device, mode of administration, 
physicochemical properties of drug molecule.  
 Viscosity  
A higher viscosity of the formulation increases contact time between the drug 
and the nasal mucosa thereby increasing the time for permeation. At the same time, 
highly viscous formulations interfere with the normal functions like ciliary beating or 
mucociliary clearance and thus alter the permeability of drugs. 
 
 
 
 
 
 
 
 
 
 
           Figure 1.9: Schematic representation of factors affecting nasal drug absorption 
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1.2.7. Nasal Drug Delivery Formulations: 
The nasal drug formulations are, 
 Nasal Drops 
 Nasal Sprays 
 Nasal Gels 
 Nasal Powders 
 Microemulsions 
 Mucoadhesives 
Nasal Drops:  
Nasal drops are one of the most simple and convenient systems developed for 
nasal delivery. Nasal drops contain therapeutically active ingredients dissolved in 
solutions or mixtures of excipients (for example, preservatives, viscosity modifiers, 
emulsifiers and buffering agents). Usually they are administered to a dropper. The 
main disadvantage of this system is the lack of dose precision. 
Nasal Sprays: 
           Both solution and suspension formulations can be formulated into nasal sprays. 
The dose can be metered by a spray pump or it may have been premetered during 
manufacture. A nasal spray unit can be designed for unit dosing or to discharge up to 
several hundred metered sprays of formulation containing the drug substance. The 
particle size and morphology (for suspensions) of the drug and viscosity of the 
formulation determine the choice of pump and actuator assembly. 
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            Nasal Gels: 
            Nasal gels are highly viscous, thickened solutions or suspensions. The 
advantages of the nasal gel include the reduction of postnasal drip due to high 
viscosity, lowering of the taste impact due reduced swallowing, less anterior leakage 
of the formulation, reduced irritation by using soothing/emollient excipient and target 
delivery to the mucosa for better absorption. 
Nasal Powders: 
            This dosage form may be developed if the drug lacks stability in the solution 
and suspension dosage forms. The other advantages of the nasal powder dosage form 
are the absence of preservatives and superior stability of the formulation. However, the 
suitability of the powder formulation is dependent on the solubility, particle size, 
aerodynamic properties and nasal irritancy of the nasal drug and/or excipients. An 
intranasal powder form of glucagon was reported to have improved the metabolic 
status and fatty liver in patients with pancreatectomy. 
Microemulsions: 
            This is thermodynamically stable, isotropically clear product that has a droplet 
size <0.15µm. It consists of an oil phase, surfactant, co-surfactant and aqueous phase. 
Oil in water (o/w) microemulsions represents a promising prospect for the 
development of formulations suitable for the incorporation of poorly water-soluble 
drugs because of high solubilization capacity as well as the potential for enhanced 
absorption by the CSF. 
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Mucoadhesives: 
             Mucoadhesive formulations using polymers such as carbopol, chitosan and 
poloxamers have been prolong the duration of contact between the nasal mucosa and 
the formulation. 
 
 
Fig 1.10: A Schematic diagram of Various absorption, distribution, and   elimination 
pathways of Intranasal administration. 
1.3.    In situ Gelling System:    (Parekh Hejal B., et.al., 2012) 
             Innovation is a key driver of growth that in the recent years there has been a 
continuous effort in the direction of achieving controlled and sustained drug delivery 
systems. Considerable attention has been received in the in situ gelling systems over 
the past few years. Research and patent in the field of In situ gels have increased in the 
past few years. It has special application in the biomedical field.  
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              Controlled and sustained drug delivery has become the necessity in modern 
pharmaceutical design and an intensive research have been undertaken in achieving 
much better drug product effectiveness, reliability and safety. This problem has been 
solved by In situ drug delivery system. 
                In situ forming polymeric formulations are drug delivery systems that are in 
sol form before administration in the body, but once administered, undergo gelation in 
situ,  to form a gel. 
 
      Fig 1.11: A Schematic diagram of Sol-gel mechanism 
 
1.3.1. Advantages of In situ gels: 
 A drug can prolong the drug contact at the site of administration due to its 
rheological and mucoadhesive properties as compared to an aqueous solution. 
 The gels also possess a broad application spectrum and can be applied in 
almost every route of administration. Oral, ophthalmic, rectal, transdermal, 
subcutaneous and vaginal gels are available for different pharmaceutical 
applications. 
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 The gel formulations can be used to enhance the local and systemic exposure 
of potential lead compounds, which ideal to establish animal models for 
various conditions quickly and cost efficiently. 
 Ease of administration and reduced frequency of administration. 
 Improved patient compliance and comfort. 
 In situ gel formulations offers an interesting alternative for achieving systemic 
drug effects of parenteral routes, which can be inconvenient of oral route, 
which can result in unacceptably low bioavailability and passes the hepatic first 
pass metabolism in particular of proteins and peptides. 
 It makes the production less complex and hence lowers the investment and 
manufacturing cost.   
1.3.2. Classification of In Situ Gel Formulation: 
Based on Route of Administration: 
 In situ polymeric system for oral administration. 
 In situ  polymeric system for ocular delivery. 
 In situ polymeric systems for rectal and vaginal delivery. 
 In situ polymeric system forming injectable drug delivery system. 
 In situ polymeric systems forming nasal drug delivery system. 
1.3.3. Importance of In Situ Gelling System: 
 The major importance is the possibilities of administrating accurate 
& reproducible quantities compared to already formed gel. 
 In situ forming polymeric delivery system such as ease of 
administration & reduced frequency of administration improved patient 
compliance & comfort. 
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 Poor bioavailability & therapeutic response exhibited by conventional 
ophthalmic solution due to rapid precorneal elimination of drug may be 
overcome by use of gel system that are instilled as drops into eye & 
undergoes a sol-gel transition from instilled dose. 
 Liquid dosage form that can sustain drug release & remain in contact 
with cornea of eye for extended period of time is ideal. 
 Reduced systemic absorption of drug drained through the nasolacrimal 
duct may result in some undesirable side effects. 
1.3.4. Ideal Characteristics of Polymer: 
A polymer used to in situ gels should have following characteristics, 
 It should be biocompatible. 
 It should be capable of adherence to mucus. 
 It should have pseudo plastic behaviour. 
 It should be good tolerance & optical activity. 
 It should influence the tear behavior. 
 The polymer should be capable of decrease the viscosity with 
increasing shear rate there by offering lowered viscosity during 
blinking & stability of the tear film during fixation. 
1.4. Mucoadhesive In Situ Gels as Nasal Drug Delivery Systems: 
            Conventionally the nasal cavity is used for the treatment of local diseases, such 
as rhinitis and nasal congestion. However, in the past few decades nasal drug delivery 
has been paid much more attention as a promising drug administration route for the 
systemic therapy. This is due to the anatomy and physiology of the nasal passage, such 
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as the large surface area, highly vascularized epithelium, porous endothelial 
membrane, and the avoidance of first-pass metabolism. 
Nasal drug delivery can also provide a route of entry to the brain that 
circumvents the blood–brain barrier because the olfactory receptor cells are in direct 
contact with the central nervous system. 
In Situ is a  Latin word which means in position.  
1.4.1. Advantages of  Mucoadhesive In situ Gels as Nasal Drug Delivery System: 
 Avoids degradation of drug in gastrointestinal tract resulting from acidic or 
enzymatic degradation. 
 Avoids degradation of drug resulting from hepatic first-pass metabolism. 
 Results in rapid absorption and onset of action. 
 Results in higher bioavailability thus uses lower doses of drug. 
 Easily accessible, non-invasive route. 
 Self-medication is possible through this route. 
 Direct transport into systemic circulation and CNS is possible Offers lower risk 
of overdose. 
 Does not have any complex formulation requirement. 
1.4.2. In situ forming hydrogels: 
There are three broadly defined mechanisms used for triggering the in situ gel 
formation of biomaterials. 
 In situ gel formation based on physiological stimuli 
(Eg., temperature and pH) 
 In situ gel formation based on chemical reactions 
        (Eg., chemical and photo-initiated polymerization). 
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1.4.2.1. In situ gel formation based on physiological stimuli 
Thermally triggered systems: 
 Eg., temperature  
 
Temperature-sensitive hydrogels are probably the most commonly studied 
class of environment-sensitive polymer systems in drug delivery research. The use of 
biomaterial whose transitions from sol to gel is triggered by increase in temperature 
provides an attractive way to approach in situ gel formation. The ideal critical 
temperature range for such system is ambient and physiologic temperature, such that 
clinical manipulation is facilitated and no external source of heat other than that of 
body is required for triggering gelation. 
Three main strategies exist in engineering of thermo responsive sol-gel 
polymeric system. For convenience, temperature-sensitive hydrogels are classified into 
negatively thermo sensitive, positively thermo sensitive and thermally reversible gels. 
Critical solution temperature (LCST) and contract upon heating above the 
LCST. Polymers with low critical solution temperature (LCST) transition between 
ambient and physiologic temperature are used for this purpose. One of the most 
extensively investigated polymers that exhibit useful LCST transition is poly (N 
isopropylacrylamide) (PNIPAAm). PNIPAAm is a water soluble polymer at its low 
LCST, but hydrophobic above LCST, which result on precipitation of PNIPAAm from 
the solution at the LCST. 
  Pluronics are poly (ethylene oxide)-poly(propylene oxide)-poly (ethylene 
oxide) (PEO-PPO-PEO) triblock co-polymers that are fluid at low temperature, but 
form thermo reversible gel when heated as a consequence of disorder-order transition 
in micelle packing which makes these polymers suitable for in situ gelation . A 
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positive temperature sensitive hydrogel has an upper critical solution temperature 
(UCST) such a hydrogel contracts upon cooling below the UCST. Polymer networks 
of poly (acrylic acid) (PAA) and polyacrylamide (PAAm) or poly (acrylamide-co-
butyl methacrylate) have positive temperature dependence of swelling. The most 
commonly used thermo reversible gels are those prepared from poly (ethylene oxide)-
b-poly (propylene oxide)-b-poly (ethylene oxide) (Pluronics®, Tetronics®, 
poloxamer).  
 pH triggered systems 
Another formation of in situ gel based on physiologic stimuli is formation of 
gel induced by pH changes. All the pH-sensitive polymers contain pendant acidic or 
basic groups that either accept or release protons in response to changes in 
environmental pH. The polymers with a large number of ionizable groups are known 
as polyelectrolytes. Swelling of hydrogel increases as the external pH  increases in the 
case of weakly acidic (anionic) groups, but decreases if polymer contains weakly basic 
(cationic) groups. The majority of anionic pH-sensitive polymers are based on PAA 
(Carbopol®, carbomer) or its derivatives. 
 Likewise, polyvinyl (Acetaldiethylamino Acetate) solutions with a low 
viscosity at pH 4 form hydrogel at neutral pH condition. Mixtures of poly (methacrylic 
acid) (PMA) and polyethylene glycol (PEG) also have been used as a pH sensitive 
system to achieve gelation. 
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1.4.2.2. In situ gel formation based on chemical reactions 
(Eg., chemical and photo-initiated polymerization). 
Chemical reactions that results in situ gelation may involve precipitation of 
inorganic solids from supersaturated ionic solutions, enzymatic processes, and photo-
initiated processes. 
Ionic cross linking 
Polymers may undergo phase transition in presence of various ions. Some of 
the polysaccharides fall into the class of ion-sensitive ones.While k-carrageenan forms 
rigid, brittle gels in replacement of small amount of K+, i-carrageenan forms elastic 
gels mainly in the presence of Ca2+. Gellan gum available commercially as Gelrite® 
is an anionic polysaccharide that undergoes in situ gelling in the presence of mono- 
and divalent cations, including Ca2+, Mg2+, K+ and Na+. Gelation of the low-
methoxypectins can be caused by divalent cations, especially Ca2+. Likewise, alginic 
acid undergoes gelation in presence of divalent/ polyvalent cations eg. Ca2+ due to the 
interaction with guluronic acid block in alginate chains. 
Photo-polymerization 
Photo-polymerization is commonly used for in situ gel formation of 
biomaterials. A solution of monomers or reactive macromers and initiator can be 
injected into a tissue site and the application of electromagnetic radiation 
used to form gel. Acrylate or similar polymerizable functional groups are typically 
used as the polymerizable groups on the individual monomers and macromers because 
they rapidly undergo photo-polymerization in the presence of suitable photo initiator. 
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                     Fig 1.12: A Schematic diagram of In situ gel formulation  
 
1.5. Migraine:                      (Viram., et al., 2012) 
Migraine is a physiologic condition, in which a person suffers from 
tremendous headache. Generally, this headache affects only one side of the head and 
body. Migraine is a neurological syndrome characterized by altered bodily 
perceptions, headaches and nausea. Physiologically the migraine headache is a 
neurological condition more common to women than to men. 
In such people, the blood flow in the brain muscles drops, as a result of too 
much load, squeezing the arteries. When the person suddenly relaxes, these tight brain 
muscles expand, stretching the blood vessel walls. The blood pumped with each 
heartbeat, then pushes the vessels further, causes immense pain. Though the exact 
cause of migraine has not been identified. There are a number of factors that can 
trigger the severe headache. The typical headache is unilateral and pulsating, lasting 
from 4 to 72 hours. 
In other words migraine is a familial disorder characterized by recurrent attacks 
of headache widely variable in intensity, frequency and duration. Migraine headaches 
results from a combination of blood vessel enlargement and the release of chemicals 
from nerve fibers that coil around these blood vessels. During the headache, an artery 
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enlarges that is located on the outside of the skull just under the skin of the temple 
(temporal artery). This causes a release of chemicals that cause inflammation, pain and 
further enlargement of the artery. 
 A migraine is a severe painful headache that is often preceded or accompanied 
by sensory warning signs such as flashes of light, blind spots, tingling in the arms and 
legs, nausea, vomiting, and increased sensitivity to light and sound. A migraine 
headache causes the sympathetic nervous system to respond with feelings of nausea, 
diarrhea, and vomiting. This response also delays the emptying of the stomach in to 
the small intestine (affecting food absorption), decreases blood circulation (leading to 
cold hands and feet) and increases sensitivity to light and sound. 
1.5.1. Causes of Migraine:       (http://www.medicalnewstoday.com/articles) 
Some people who suffer from migraines can clearly identify triggers or factors 
that cause the headaches, but many cannot.  Potential migraine triggers include: 
 Allergies and allergic reactions 
 Bright lights, loud noise and certain odors and perfumes 
 Physical or emotional stress 
 Changes in sleep patterns or irregular sleep 
 Smoking or exposure to smoke 
 Skipping meals or fasting 
 Alcohol 
 Menstrual cycle fluctuations, birth control pills hormone fluctuations 
during menopause onset. 
Triggers do not always cause migraines, and avoiding triggers does not always prevent 
migraines. 
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                      Fig 1.13: A Schematic diagram of causes of migraine 
 
 
 
 
 
 
 
 
                                
  
                      Fig 1.14: A Schematic diagram of triggers of migraine 
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1.5.2. Symptoms of Migraine: 
 Symptoms of migraine can occur a while before the headache, immediately 
before the headache, during the headache, and after the headache. Although not all 
migraines are same, typical symptoms are include: 
 Moderate to severe pain, usually confined to one side of the head, but 
switching in sucessessive migraines. 
 Pulsing and throbbing head pain 
 Increasing pain during physical activity 
 Inability to perform regular activities due to pain 
 Nausea, vomiting and increased sensitivity to light and sound 
1.5.3. Stages of migraine:         (http://www.nhs.uk/conditions/migraine) 
There are five distinct stages to a migraine, although not everyone goes 
through all these stages, 
Prodromal (Pre-headache) stage: 
Some people experience change in moode, energy levels, behavior and 
appetite, and sometimes aches and pains several hours or days before an attack. 
Sometimes also referred to as the “premonitory stage” this phase can begin hours or 
even days prior to the onset of the acute pain phase. It may be characterized by 
sleepiness, irritability, and other change in mood or any number of diverse symptoms 
specific to the individual sufferer. About half of all migraine patients report consistent 
awareness of a prodrome stage. They ‘just know’ when a migraine is coming. 
However, it has been found that about 80% of those with migraine can learn to 
recognize a prodrome stage. 
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 Aura: 
 Some people experience in a sensation, or aura, just before their migraine 
starts. Symptoms of aura include flashes of light or blind spots, difficulty focusing, 
and seeing things as if you are looking through a broken mirror. The aura usually 
develops over 5-20 minutes and lasts less than 60 minutes. The aura is not harmful and 
results in no permanent damage. But for someone who has never had a migraine, or 
never had an aura, the experience can be a very frightening one. 
 The aura usually disappears before the start of headache pain, which usually 
follows the aura by a few minutes to an hour. Infrequently the aura may continue 
during the time of headache pain. Even more infrequently the headache pain may 
never arrive. When an aura is not followed by a headache, it is called a migraine 
equivalent, acephalic migraine or silent migraine. 
 Headache Stage or Acute Pain Stage: 
This is usually a pulsating or throbbing pain on one side of the head. The 
characteristic feature of migraine disease is, of course, the migraine headache. But 
even the term, “migraine headache” is, if not entirely misleading, at least deficient. 
While the headache pain may be severe, the symptoms of an acute attack are not 
limited to pain. Migraine headache is accompanied by a host of autonomic symptoms. 
These may include nausea, vomiting, aversion to bright lights (photophobia), aversion 
to loud sounds (phonophobia), aversion to strong odors (osmophobia), and any number 
of other symptoms. This stage lasts for 4 to 72 hours. 
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The headache of migraine generally exhibits at least some of the following 
characteristics: 
 Throbbing, pounding, or pulsating pain 
 Often on just one side of the head, or begins on one side before spreading to 
both sides 
 Pain may alternate sides from one attack to the next 
 Made worse with mild activity, such as walking or bending 
 Most intense pain is often concentrated around the temple(s) – on the side of 
the forehead 
 Commonly lasts from 4 to 72 hours in adults, 30 minutes to 48 hours in 
children 
 Nausea is reported by almost 90% of migraine sufferers 
 Vomiting may occur with up to 35% of migraine attacks 
Resolution Stage: 
Most attacks gradually fade away. Some people find the headache stops 
suddenly after they have been sick. Sleep have been relieves the symptoms. 
Postdromal or Recovery phase: 
There may be a stage of exhaustion and weakness afterwards. Simply stated, 
the migraine headache is gone but migraine disease remains active. Commonly, 
patients experience migraine-associated non-headache symptoms for an additional 24 
to 48 hours. Given an average prodrome stage lasting 24 hours, an acute pain stage 
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 That averages 24-48 hours and post-headache impairment lasting an additional 24-48 
hours, the total duration of migraine impairment, per attack, can be from three to six 
days. Of course some attacks are more or less severe, and the extent to which migraine 
impairs functioning is obviously greatest during the acute pain stage. Nonetheless, 
considering that a person with moderate migraine disease may experience two to four 
attacks per month, it is often the case that there are more days with migraine 
impairment than there are without migraine impairment. 
There are several types of Migraine: 
 Migraine with Aura is when there is a warning sign, known as aura, before 
the migraine begins. Warning sounds may include visual problem (such as 
flashing lights) and stiffness in the neck, shoulders or limbs. 
 Migraine without Aura 
 Migraine without Headache also known as silent migraine is when an aura or 
other migraine symptoms are experienced but a headache does not develop. 
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Fig 1.15: A Schematic diagramatic representation of stages of migraine 
 
1.5.4. Diagnosis of Migraine: 
The International Headache Society recommends the following criteria to 
diagnose migraines without aura. This stands for: 
 5 or more attacks 
 4 hours to 3 days in duration 
 At least 2 of unilateral location, pulsating quality, moderate to severe pain 
aggravation by or avoidance of routine physical activity 
 At least 1 additional symptoms such as nausea, vomiting, sensitivity to light, 
sensitivity to sound. 
 Tests such as electroencephalography (EEG), computed tomography (CT), 
magnetic resonance imaging (MRI) and spinal tap may also been performed 
that check for: 
 Bleeding within the skull 
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 Blood clot within the membrane 
 Stroke 
 Dilated blood vessels in the brain 
 Too much or too little cerebrospinal fluid 
 Inflammation of the membranes of the brain or spinal cord 
 Nasal sinus blockage 
 Postictal headache (after stroke or seizure) 
 Tumors 
1.5.5. Prevention and treatment of migraine: 
                                (http://www.mayoclinic.com/health/migraine-headache) 
      Migraine treatment (abortive therapies) and prevention (prophylactic therapies) 
focus on avoiding triggers, controlling symptoms, and taking medicines. 
 Preventive Migraine Medication 
Antimigraine drugs or drugs that prevent migraine or cure migraine are classified 
as follows: 
  Beta Blockers: The drugs prevent the widening of the arteries in your head by 
blocking the beta receptors. 
 Anticonvulsants: These drugs treat seizures. Like many preventative migraine 
medications, they increase levels of an amino acid known as GABA, which 
may play an important in migraine development. 
 Methysergide: This is one of the more toxic medications, and so is usually 
reserved for more serious cases. 
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 Calcium Channel Blockers: These medications have the ability to stop the 
spasm of the arteries, block the release of serotonin and inhibit platelet 
clumping. 
 Antidepressants: It's believed that the anti-migraine effect of these medicines 
is a whole different reaction than what happens when treating depression. 
 Clonidine: Clonidine is an alpha blocker that also protects the blood vessels. 
 Cyproheptadine: It's most often prescribed to children, and seems to be only 
slightly effective for adults.  
 NSAIDs: Though primarily used to stop headaches once they start, they have 
also been used as a preventative medication. 
 Combinations: Sometimes combinations of the above types of drugs will be 
prescribed.  
 Abortive Migraine Medication 
Depending on your physical check up and past history, your doctor may prescribe 
treatment to stop the headaches once they have started. Medicines to treate migraines 
are called "abortive medications" and include:  
 Analgesics with caffeine like Excedrin® Migraine (acetaminophen aspirin and 
caffeine) 
 Analgesics with caffeine and barbiturates lie Fiorinal® and Fioricet®. 
 Non steroidal anti-inflammatory drugs (NSAIDs) like Advil® and Aleve®. 
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Fig 1.16: A Schematic diagrammatic representation of Treatment of migraine  
1.5.6. Popular Migraine Medicines 
 Inderal (propranolol) 
 Blocadren (timolol) 
 Toprol (metoprolol) 
 Corzide (nadolol) 
 Triptans 
 Dihydroergotamine 
 Prochlorperazine 
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 Depakene (sodium valproate) 
 Depakote (divalproex sodium) 
 Isoptin (Verapamil) 
 Nimotop (Nimodipine) 
 Elavil 
 Sinequan 
 Norpramin 
 Proza                                     
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2. LITERATURE SURVEY 
2.1. Literature Review 
       1)    Swamy. N. G. N., et al. (2012):  had reported that In situ forming 
polymeric formulations are drug delivery systems that are in sol form before 
administration in the nasal cavity, but once administered, undergo gelation in situ, to 
form a gel. The formation of gel depends on factors like temperature modulation, pH 
change, presence of ions and ultra violet irradiation, from which the drug gets 
released in a sustained and controlled manner. Mucoadhesive in situ gel formulations 
have demonstrated increase in the residence time in the nasal cavity as well 
enhancement of the permeation characteristics of the drug. The in situ gel forming 
polymeric formulations offer several advantages like sustained and prolonged action 
in comparison to conventional drug delivery systems. With a brief introduction to 
nasal drug delivery, in this paper, the use of novel mucoadhesive in situ gels for the 
intranasal delivery of drugs is reviewed along with methods available for evaluation 
of in situ gels. 
 2)   Swati Pund., et al. (2012): had reported that Venlafaxine, a dual acting 
antidepressant is a new therapeutic option for chronic depression. They analyzed the 
transport of Venlafaxine through sheep nasal mucosa. Transmucosal permeation 
kinetics of Venlafaxine was examined using sheep nasal mucosa mounted onto static 
vertical Franz diffusion cells. Nasal mucosa was treated with Venlafaxine in situ gel 
(100 µl,1% w/v) for 7 h. Amount of Venlafaxine diffused through mucosa was 
measured using validated RP-HPLC method. After the completion of the study 
histopathological investigation of mucosa was carried out. Ex vivo studies through 
sheep nasal mucosa showed sustained diffusion of Venlafaxine with 66.5% 
Nasal in situ gel of Rizatriptan Benzoate Literature survey 
Adhiparasakthiparasakthi college of pharmacy, Melmaruvathur. Page 53 
permeation in 7 h. Histopathological examinations showed no significant adverse 
effects confirming that the barrier function of nasal mucosa remains unaffected even 
after treatment with Venlafaxine in situ gel. Permeation through sheep nasal mucosa 
using in situ gel demonstrated a harmless nasal delivery of Venlafaxine, providing 
new dimension to the treatment of chronic depression. 
3)  Yuan Yuana., et al. (2012): had reported that Poloxamer 407 has excellent 
thermo-sensitive gelling properties. The main aim of the present investigation was to 
develop thermo sensitive and mucoadhesive rectal in situ gel of Nimesulide (NM) by 
using mucoadhesive polymers such as sodium alginate (Alg–Na) and HPMC. These 
gels were prepared by addition of mucoadhesive polymers (0.5%) to the formulations 
of thermosensitive gelling solution containing poloxamer 407 (18%) and Nimesulide 
(2.0%). Polyethylene glycol (PEG) was used to modify gelation temperature and drug 
release properties. The gelation temperature and drug release rate of the prepared in 
situ gels were evaluated. Gelation temperature was significantly increased with 
incorporation of Nimesulide (2.0%) in the poloxamer solution, while the addition of 
the mucoadhesive polymers played a reverse role on gelation temperature. The 
addition of PEG polymers increased the gelation temperature and the drug release 
rate. Among the formulations examined, the poloxamer 407/Nimesulide/sodium 
alginate/PEG 4000 (18/2.0/0.5/1.2%) exhibited the appropriate gelation temperature, 
acceptable drug release rate and rectal retention at the administration site.  
4)  Bhandwalkar M.J., et al. (2012): had reported that in order to improve 
the bioavailability of the antidepressant drug, Venlafaxine hydrochloride, in situ 
mucoadhesive thermoreversible gel, was formulated using Lutrol F127 (18%) as a 
thermo gelling polymer. Mucoadhesion was modulated by trying carbopol 934, PVP 
K30, HPMC K4M, sodium alginate, tamarind seed gum, and carrageen an as 
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mucoadhesive polymers. Results revealed that as the concentration of mucoadhesive 
polymer increased the mucoadhesive strength increased but gelation temperature 
decreased. Formulation was optimized on the basis of clarity, pH, gelation 
temperature, mucoadhesive strength, gel strength, viscosity, drug content, diffusion 
through sheep nasal mucosa, histopathological evaluation of mucosa, and 
pharmacodynamic study in rats.  
5)  Jyotivardhah Jaiswal., et al. (2012): had reported  Metoprolol 
Succinate undergoes hepatic first pass metabolism and hence it shows poor 
bioavailability. The objective of present research work is to improve bioavailability 
by formulating thermo reversible in-situ nasal gel. Formulation was developed to 
reduce the mucociliary clearance by using mucoadhesive polymer in gel, thereby 
increasing the contact time with nasal mucosa and hence improving the absorption of 
drug. The in-situ gelation was achieved by the use of pluronic F127, which exhibits 
thermo reversible gelation property and Sodium alginate was used as the 
mucoadhesive agent. Gels were prepared by cold technique method and characterized 
by Gelation Temperature, Permeation Studies, Histopathological Evaluation, pH, 
Drug Content, Rheological studies, Gel strength and drug polymer interaction study.   
6) Shital Uttarwar.,  et al. (2012): had reported " Gel" is the state between 
the liquid and solid which consists of physically cross linked networks of long 
polymer molecules with liquid molecules trapped within a three dimensional 
polymeric network swollen by a solvent. The aim of present study was formulation of 
in situ gelling system for nasal administration for an antiemetic drug Ondansetron 
Hydrochloride by using Pluronics 127P and Pluronics 68. All the formulations 
showed compliance with pharmacopoeial standards. 
 
Nasal in situ gel of Rizatriptan Benzoate Literature survey 
Adhiparasakthiparasakthi college of pharmacy, Melmaruvathur. Page 55 
7) Pramod K. Kolsure., et al. (2012): had Developed the  thermo reversible 
Zolmitriptan nasal gel was aimed to improve absorption and patient compliance. In 
the present research work, mixture of pluronic F-127 (Poloxamer 407) and pluronic F-
68 (Poloxamer 188) were used to confer temperature- sensitive gelation property. To 
modulate the gel strength and biadhesive force for Zolmitriptan nasal gel, bioadhesive 
polymers such as sodium alginate, sodium carboxyl methyl cellulose and polyvinyl 
pyrollidine (PVP K-25) were investigated. Incorporation of 25% w/w Zolmitriptan in 
the nasal showed no effect on the gelation temperature of the pluronic mixtures, while 
addition of the bioadhesive polymers reinforced the gel strength and the bioadhesive 
force of the prepared nasal gel formulation. The effect was most pronounced with 
sodium alginate. Increasing the concentration of bioadhesive polymers retarded the 
release of Zolmitriptan from the pluronic gel. PVP has less effect on the drug release. 
Histopathological examination of sheep nasal mucosa with control and optimized 
formulation did not show an y histological damage to the nasal tissue. 
8) Parmar Viram., et al. (2012): had reported that oral Metoclopramide 
hydrochloride undergoes first-pass metabolism. Nasal delivery could protect drugs 
from this effect. Mucoadhesive in situ gels for Metoclopramide hydrochloride with 
gellan gum were formulated and evaluated. Metoclopramide Hydrochloride Insitu 
nasal gels (10% w/w) were prepared at concentration of gellan gum 0.2%, 0.4%, 0.6% 
and 0.8% w/v with xanthan gum 0.1%, 0.15% and 0.2% w/v as bioadhesive polymer 
and benzalkonium chloride ( 0.01%) as preservative. The formulation were evaluated 
by slower release rate during the first hr, Release kinetics followed diffusion model. 
Microscopic results did not show any mucosal changes after diffusion study of the 
optimized formulation. 
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9)   Dattatraya J. Yadav., et al. (2012): had reported that  aimed to 
formulate and evaluate Nasal drug delivery system containing Salbutamol Sulphate 
was prepared for improving the bioavailability & sustaining the drug release. 
Salbutamol sulphate is a selective β2 adrenoreceptor agonist and rapidly absorbed 
from gastro intestinal tract but it is subjected to first pass metabolism. Thus oral 
bioavailability is only 50%. The main objective of present work is to enhance the 
bioavailability; reducing the dose. Thermoreversible, bioadhesive polymers such as 
poloxamer and Hydroxy Propyl Methyl Cellulose (HPMC) in the form of in situ gel 
by cold technique. The results revealed that as the increase of bioadhesive polymer 
HPMC concentration, decrease in gelation temperature (T1) and increase in gel 
melting temperature (T2). pH of all formulation were found to be within the range 
between 5.5 to 6. The drug content for all formulation was found to be 96%-100%. 
The mucoadhesive test indicates that the level of HPMC increases, the mucoadhesive 
strength also increases. The developed formulations had optimum viscosity. The 
optimized formulation shows the controlled drug release. 
10)  Kote Amol P., et al. (2011): had reported that nasal drug delivery 
system offers lucrative way of drug delivery of both topical and systemic therapies. 
The high permeability, high vasculature and low enzymatic environment of nasal 
cavity are well suitable for systemic delivery of drug molecules via nose. The 
noninvasiveness and self administrative nature of nasal delivery also attracts the 
formulation scientists to deliver protein and peptide compounds. Despite of all the 
advantages of nasal drug delivery, the bioavailability of nasally administered 
products, especially for protein and peptide molecules, is affected by many barriers 
such as physiological barriers, physicochemical barriers, and formulation barriers. 
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This review will focus on the various bioavailability barriers in nasal drug delivery 
and the strategies to improve the bioavailability of nasal dosage form. 
11) Gowda D.V., et al. (2011): had reported that the objective of present 
investigation was to develop a mucoadhesive in-situ gel; formulation was developed 
to have a controlled kinetic drug release and to minimize the toxic effects of diltiazem 
Hydrochloride (DTZ). DTZ was incorporated into the, blends of thermoreversible, 
bioadhesive polymers such as poloxamer (PLX) and Hydroxy Propyl Methyl cellulose 
(HPMC) in the form of in-situ gel by cold technique to reduce mucociliary clearance, 
and thereby it will increase the contact of formulation with nasal mucosa and hence 
improving the absorption of drug. The drug release performance was greatly affected 
by bio polymers used and their compositions in the in situ gels preparation, which 
allows absorption in nasal mucosa. 
12) Pranshu Tangri., et al. (2011): had reported a brief idea bioadhesive 
delivery systems based on hydrogels to biological surfaces that are covered by mucus. 
Techniques that are frequently used to evaluate the mucoadhesive drug delivery 
systems are discussed.. Mucoadhesion is a complex phenomenon which involves 
wetting, adsorption and interpenetration of polymer chains. Mucoadhesive drug 
delivery systems is one of the most important novel drug delivery systems with its 
various advantages and it has a lot of potential in formulating dosage forms for 
various chronic diseases. 
13)  Nazar H., et al. (2011): had reported that the development of a 
thermosensitive drug-delivery vehicle for nasal delivery, a systematic series of N-
trimethyl chitosan chloride polymers, synthesized from chitosans of three different 
average molecular weights, have been co-formulated into a hydrogel with poly 
(ethylene glycol) and glycerophosphate. Rheological evaluations have shown that 
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hydrogels derived from N-trimethyl chitosan with a low degree of quaternisation and 
high or medium average molecular weight exhibit relatively short sol–gel transition 
times at physiologically relevant temperatures. Also, the same hydrogels display good 
water-holding capacity and strong mucoadhesive potential, and their mixtures with 
mucus exhibit rheological synergy. An aqueous hydrogel formulation, derived from 
N-trimethyl chitosan of medium average molecular weight and low degree of 
quaternisation, appears particularly promising in that it exhibits most favorable 
rheological and mucoadhesive behavior and a sol–gel transition that occurs at 32.5 0 C 
within 7min. 
14)   Khan S., et al. (2010): had reported that mucoadhesive temperature-
mediated in situ gel formulations using chitosan and hydroxyl propyl methyl cellulose 
were used to enhance intranasal (i.n.) delivery of the dopamine D2 agonist ropinirole 
to the brain. Formulations were tested for gelation time, thermosensitivity, 
mucoadhesion, in vitro release and permeation, in- vitro cytotoxicity, nasal clearance, 
in vivo bioavailability and brain uptake. 
15)   Alagusundaram. M., et al. (2010):  had reported the use of the nasal 
route for the delivery of challenging drugs such as small polar molecules, vaccines, 
hormones, peptides and proteins has created much interest in nowadays. Due to the 
high permeability, high vasculature, low enzymatic environment of nasal cavity and 
avoidance of hepatic first pass metabolism are well suitable for systemic delivery of 
drug molecule via nose. Many drug delivery devices for nasal application of liquid, 
semisolid and solid formulation are investigated to deliver the drugs to the treat most 
crisis CNS diseases (i.e., Parkinson’s disease, Alzheimer’s disease) because it requires 
rapid and/or specific targeting of drugs to the brain. It is well suitable for the delivery 
of biotechnological products like proteins, peptides, hormones, DNA plasmids for 
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DNA vaccines to give enhanced bioavailability. This review sets out to discuss some 
factors affecting nasal absorption, bio-availability barriers, strategies to improve nasal 
absorption, new developments in nasal dosage form design and applications of nasal 
drug delivery system. 
16)  Rahisuddin., et al. (2010): had reported that the aim of the present 
investigation is to explain the recent advancement of nasal drug delivery system. 
Intranasal therapy has been an accepted form of treatment in the Ayurvedic system of 
Indian Medicine. The interest in intranasal delivery of drugs as a non‐invasive is 
increased. They had  also discussed advantages, disadvantages, mechanism of action 
and application of nasal drug delivery system in local delivery, systematic delivery, 
and nasal vaccine and CNS delivery of the drug. They were discussed here relevant 
aspects of biological, physicochemical and pharmaceutical factors of nasal cavity that 
must be considered during the process of discovery and development of new drugs for 
nasal delivery as well as in their incorporation into appropriate nasal Pharmaceutical 
formulations. Nasal route is more suitable for those drugs which cannot be 
administered orally due to gastric degradation or hepatic first pass metabolism of the 
drug. Intranasal drug delivery is found much promising route for administration of 
peptides and protein drugs. 
17) Varsha Gaikwad., et al. (2010): The objective of present investigation 
was to develop a mucoadhesive in-situ gel: formulation was developed with aim to 
reduce the mucociliary clearance by using mucoadhesive polymer in gel, thereby 
increasing the contact of formulation with nasal mucosa and hence improving the 
absorption of drug. The in-situ gelation was achieved by the use of pluronic F127, 
which exhibit thermoreversible geleation property. The formulation additives are 
having effect on thermodynamic of phase transitions at gelation (TI) and gel melting 
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(T2) temperature. Result revealed that addition of mucoadhesive polymer 
carbopol934 has decreased T1 whereas addition of PEG400 increased T1 PEG400 
increased in-vitro drug release shows that with increasing carbopol concentration 
increases viscosity formulation and influences the diffusion of drug particle while 
addition of PEG 400 enhances in vitro drug release. 
18)  Shyam D. Badgujar., et al. (2010): had reported that Sumatriptan 
Succinate is a 5-HT1D (5-hydroxy tryptamine 1d)-receptor agonist, used in the 
treatment of migraine and cluster headache Sumatriptan Succinate has been shown to 
have a low oral bioavailability in human volunteers (15%) because of high first pass 
metabolism. Subcutaneous administration is an alternative: however, dislike of 
injections or inability to self-administer by this route makes subcutaneous treatment 
unacceptable to some individuals. These all above things justify a need of nasal drug 
delivery. To improve the nasal retention time of Sumatriptan Succinate, it has been 
formulated as in situ mucoadhesive gel by using pluronic PF127 and carbopol 974P. 
The objective of this work was to improve the nasal bioavailability of Sumatriptan 
Succinate by increasing its nasal retention time as well as by means of nasal 
permeation. Nasal permeation of Sumatriptan Succinate was improved by using fulvic 
acid extracted from shilajit as a novel permeation enhancer. 
19)  Bhanushali., et al. (2009): The objective of this study was to develop 
intranasal nanoemulsion and gel formulations for Rizatriptan Benzoate for prolonged 
action. Nanoemulsion formulation were prepared by constructing pseudo-ternary 
phase diagrams using lipophilic and hydrophilic surfactants and water. Various 
mucoadhesive agents were tried out to form thermo-triggered mucoadhesive 
nanoemulsion. Mucoadhesive gel formulation of Rizatriptan were prepared using 
different ratios of HPMC and carbopol 980.Comparative evaluation of intranasal 
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nanoemulsions and intranasal mucoadhesive gel indicated that grater brain-targeting  
could be achieved with nanoemulsions. 
20)  Shi-lei Caoa., et al. (2009): had explain the main purpose of this study 
was to prepare a novel in situ gel system for nasal delivery of MF and study its 
efficacy on allergic rhinitis model. An ion-activated in situ gel was developed and 
characterized with gellan gum as a carrier. The system was stable kept at 40±2 ◦C for 
6 months, and the micrographic results showed that in situ gel was safety without 
mucosa irritation when given at 20µg once daily for 1 month to rats with allergic 
rhinitis. MF in gellan gum produced obviously effect on allergic rhinitis at the doses 
of 20µg/body following intranasal administration, and the efficacy was significantly 
superior to that of the common suspension (P < 0.01). The in situ gel system is a 
promising approach for the intranasal delivery of MF for the therapeutic effects 
improvement. 
21) Noha M. Zai., et al. (2007): had reported the objective of the present 
investigation was to develop a mucoadhesive in situ gel with reduced nasal 
mucociliary clearance in order to improve the bioavailability of the antiemetic drug, 
Metoclopramide Hydrochloride (MCP HCl). The in situ gelation upon contact with 
nasal mucosa was conferred via the use of the thermogelling poloxamer 407 whereas 
mucoadhesion and drug release enhancement were modulated via the use of 
mucoadhesive and polyethylene glycol (PEG) polymers respectively. The study point 
to the potential of mucoadhesive nasal in situ gel in terms of ease of administration, 
accuracy of dosing, prolonged nasal residence and improved drug bioavailability. 
22)  Michael I., et al. (2005): had reported that nasal drug delivery has now 
been recognized as a very promising route for delivery of therapeutic compounds 
including biopharmaceuticals. It has been demonstrated that low absorption of drugs 
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can be countered by using absorption enhancers or increasing the drug residence time 
in the nasal cavity, and that some mucoadhesive polymers can serve both functions. 
This article reviews the background of nasal mucoadhesive drug delivery with special 
references to the biological and pharmaceutical considerations for nasal 
mucoadhesive drug administration. 
23)  Ketousetuo Keotsu., et al. (2005): had developed using a natural 
mucoadhesive agent obtained from the fruit of Delinia Indica L.The mucoadhesive 
strength and viscosity of this natural mucoadhesive agent was found to be higher in 
comparison to the synthetic polymers, namely hydroxyl propyl methyl cellulose 
(HPMC) and carbopol 934, which are conventionally used for a similar purpose. 
Invitro drug release characteristics using a Franz-diffusion cell and excised bovine 
nasal membrane was also found to be better in comparison to the above synthetic 
polymers. This patient friendly, needle free dosage form may replace the Oxytocin 
injections in the future. 
24) Sudipta Ganguly., et al. (2004): had reported  the objective of this study 
was to develop a novel chitosan-glyceryl monooleate (GMO) in situ gel system for 
sustained drug delivery and targeting. The delivery system consisted of 3% (w/v) 
chitosan and 3% (w/v) GMO in 0.33M citric acid. In situ gel was formed at a 
biological pH.  In vitro release studies were conducted in Sorensen’s phosphate buffer 
(pH 7.4) and drugs were analyzed either by HPLC or spectrophotometry. 
Characterization of the gel included the effect of cross-linker, determination of 
diffusion coefficient and water uptake by thermogravimetric analysis (TGA). 
Mucoadhesive property of the gel was evaluated in vitro using an EZ-Tester. 
Incorporation of a cross-linker (glutaraldehyde) retarded the rate and extent of drug 
release. The in-vitro release can further be sustained by replacing the free drug with 
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drug-encapsulated microspheres. Drug release from the gel followed a matrix 
diffusion controlled mechanism. Inclusion of GMO enhanced the mucoadhesive 
property of chitosan by three to seven fold. This novel in situ gel system can be useful 
in the sustained delivery of drugs via oral as well as parenteral routes. 
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   (http:// www.google.com, drug bank; http://en.wikipedia.org/wiki/Rizatriptan; 
http://www.rxlist.com/cgi/generic2/rizatrip.htm; 
http://www.drugs.com/cdi/rizatriptan.html)  
Rizatriptan Benzoate: 
Rizatriptan Benzoate is a class of Serotonin 5HT1 receptor antagontst. 
1. Synonyms        :  MK 462 Free Base Rizatriptan, Rizatriptan benzoat, 
    Rizatriptan benzoate. 
2. Molecular formula    :  C15H19N5•C7H6O2 
3. Molecular weight       :  391.47 
4. IUPAC Name            :  dimethyl({2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H- 
indol-3-yl]ethyl})amine        
5. Chemical name  :  N,N-Dimethyl-5-(1H-1,2,4-triazol-1-yl-methyl)-1H- 
  indole-3- ethanamine monobenzoate 
6. CAS number       :  145202-66-0 
7.  Category        :  Anti-migraine drug. 
8. Melting point       :  178-180°C  
9. Structural formula: 
 
 
 
 
 
 
 
2.2. DRUG PROFILE 
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10. Solubility: 
 Soluble in water 42 mg/mL (for free base). 
11. Description:  
 Off white crystalline solid 
 characteristic odour 
12. Pharmacokinetic data: 
 Bioavailability   :  45% 
 Protein binding   :  14% 
 Metabolism     :  Extensive First pass metabolism (MAO-A involved) 
 Half-life     :  Approximately 2-3 h. 
 Volume of distribution : 140L in men, 110L in women 
 Excretion      :  Renal  
 Pka                  :  Strongest acedic: 17.24 , Strongest basic: 9.56 
 logP       :  1.4 
 Nature      :  Hydrophilic 
13. Dosage and Administration: 
                   Table 2.1: Table indicating dosage Forms & Strengths 
 
 
 
 
 
 
 
 
 
 Adults  
PO 5 or 10 mg per migraine attack. A second dose may be repeated after a 
minimum of 2 h as needed (max, 30 mg per 24 hours). 
 
 
S.NO 
 
DOSAGE FORMS 
 
STRENGTHS 
1 Tablets 5mg 
10mg 
2 Tablets 
orally disintegrating 
5mg 
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 Children (6 to 17 y of age)  
PO For weight 40 kg or more, 10 mg per migraine attack; for weight 39 kg or 
less, 5 mg per migraine attack. 
Concomitant therapy with propranolol 
 Adults  
PO Only the 5 mg dose of rizatriptan is recommended, up to a maximum of 3 
doses per 24 h (15 mg). 
 Children (6 to 17 y of age)  
PO For weight 40 kg or more, only a single 5 mg dose of rizatriptan is 
recommended (max, 5 mg per 24 h). Do not coadminister rizatriptan and propranolol 
to patients who weigh less than 40 kg. 
General Advice 
 The safety of treating, on average, more than 4 headaches in a 30-day period 
has not been established. 
 If a patient has no response to the first dose of rizatriptan, the diagnosis of 
migraine should be reconsidered before administration of a second dose. 
 Administration of the disintegrating tablets with liquid is not necessary. 
14. Mechanism of action: 
 Three distinct pharmacological actions have been implicated in the antimigraine 
effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves 
to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal 
nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) 
vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-
HT1B receptor agonism. 
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15. Therapeutic uses 
 Vasoconstrictor Agents 
 Anti-inflammatory Agents 
 Anti-migraine Agents 
 Selective Serotonin Agonists 
16. Toxicities: 
 Symptoms of overdose include dizziness, fainting, heart and blood vessel 
problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, 
and vomiting. 
17. Drug interactions  
5-HT 1 agonists (eg, sumatriptan)  
Increased risk of vasospastic reactions; therefore, coadministration of two 5-HT 1 
agonists within 24 h of each other is contraindicated. 
Ergot-containing drugs (eg, ergotamine)  
Additive and prolonged vasospasm. Coadministration within 24 h is 
contraindicated. 
MAOIs (eg, phenelzine)  
Use of rizatriptan with MAOIs or within 14 days following discontinuation of an 
MAOI is contraindicated. 
Propranolol  
Increased rizatriptan plasma concentrations. The dose of Rizatriptan should be 
adjusted. 
Serotonin syndrome has been reported during coadministration of SSRIs, SNRIs, 
or TCAs and selective 5-HT 1 agonists. The onset of serotonin syndrome can occur 
within minutes to hours of receiving a new or a greater dose of a serotonergic 
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medication. Rizatriptan treatment should be discontinued if serotonin syndrome is 
suspected. 
18. Adverse Reactions: 
       Cardiovascular 
 Palpitation (at least 1%); coronary artery vasospasm; hypertension; MI; stroke; 
transient myocardial ischemia; ventricular tachycardia; ventricular fibrillation. 
CNS 
 Dizziness (9%); somnolence (8%); asthenia/fatigue (7%); paresthesia (4%); 
headache (2%); euphoria, hypoesthesia, tremor (at least 1%); seizure (postmarketing). 
GI 
Nausea (6%); dry mouth (3%); abdominal discomfort, diarrhea, vomiting (at least 
1%); dysgeusia (postmarketing). 
Hypersensitivity 
Allergic conditions, including anaphylaxis/anaphylactoid reaction, angioedema, 
wheezing, and TEN (postmarketing). 
Miscellaneous 
Pain and other pressure sensations (9%); atypical sensations (5%); localized pain, 
pain, tightness, pressure, and/or heaviness of chest (3%); regional tightness, pressure, 
or heaviness, tightness, pain, or pressure of neck, throat, or jaw (2%); dyspnea, 
flushing, warm sensations (at least 1%). 
19. Precautions: 
General Precautions 
 Ocular Effects 
 Possible accumulation of rizatriptan in melanin-rich tissues (e.g., eye) over 
time, resulting in potential toxicity in these tissues with extended use.  
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 Phenylketonuria  
 Advise individuals who must restrict phenylalanine intake that each 5- or 
10-mg Maxalt-MLT orally disintegrating tablet contains aspartame, which 
is metabolized in GI tract to provide 1.05 or 2.1 mg of phenylalanine, 
respectively. Conventional tablets do not contain aspartame. 
20. Brand names : 
           Table 2.2: Table indicating brand names& manufactures 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21. Storage/Stability 
 
     Store between 59° and 86°F. 
 
 
 
 
 
 
Brand names 
 
 
Manufactures 
 
Maxalt RPD 
 
 
Merck Sharp & Dohme, Chile 
 
 
Maxalt 
 
 
Merck Sharp & Dohme, Austria; MSD, 
South Africa 
 
 
Maxalt-Rapidisc 
 
 
Merck Sharp & Dohme, Turkey 
 
 
Rizact 
 
 
Cipla, India 
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2.3.1. CARBOPOL 974 P:        
                                   ( Raymond C. R., 2003; www.pharma.lubrizol.com) 
1. Nonproprietary Names: 
 BP: Carbomers 
 PhEur: Carbomer 
 USP-NF: Carbomer 
2. Synonyms                                  : carboxypolymethylene; carbomers.  
3. Chemical Name and CAS Registry Number : Carbomer [9003-01-4] 
 
 4. Empirical Formula           : C5H10O2 
 
5. Molecular Weight                        : 86,000 
 
6. Structural Formula : 
  
 
 
 
 
 
7. Functional Category:  
   Stabilizing agent, Bioadhesive material, Controlled-release agent, Emulsifying 
agent, Emulsion stabilizer, Rheology suspending agent, Tablet binder. 
 
2.3.POLYMERS PROFILE 
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8. Applications in Pharmaceutical Formulation or Technology: 
 
Carbomers are used in liquid or semisolid pharmaceutical formulations as 
rheology modifiers. Formulations include creams, gels, lotions and ointments for use 
in ophthalmic, rectal, topical and vaginal preparations. Carbomer polymers have also 
been investigated in the preparation of sustained-release matrix beads, as enzyme 
inhibitors of intestinal proteases in peptide-containing dosage forms, as a bioadhesive 
for a cervical patch and for intranasally administered microspheres, in magnetic 
granules for site-specific drug delivery to the esophagus, and in oral mucoadhesive 
controlled drug delivery systems. 
 Use                                       Concentration (%) 
 Emulsifying agent                    0.1–0.5 
 Gelling agent                            0.5–2.0 
 Suspending agent                     0.5–1.0 
 Tablet binder                            0.75–3.0 
 Controlled-release agent          5.0–30.0  
9. Description:  
         Carbomers are white-colored, ‘fluffy’, acidic, hygroscopic powders with a 
characteristic slight odor. 
10. Typical properties: 
 Acidity/alkalinity:   pH = 2.7–3.5 for a 0.5% w/v aqueous dispersion; 
                                               pH = 2.5–3.0 for a 1% w/v aqueous dispersion. 
 Density (bulk):   1.76–2.08 g/cm3 
 Density (tapped):  1.4 g/cm3 
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 Melting point:  Decomposition occurs within 50 minutes at 260°C.  
 Dissociation constant: pKa = 6.5-0.5 
 Glass transition temperature: 100–105.8°C 
 Moisture content: Typical water content is up to 2% w/w. However, 
carbomers are hygroscopic and a typical equilibrium moisture content at 258C 
and 50% relative humidity is 8–10% w/w. The moisture content of a carbomer 
does not affect its thickening efficiency, but an increase in the moisture 
content makes the carbomer more difficult to handle because it is less readily 
dispersed. 
 Solubility: Swellable in water and glycerin and, after neutralization, in ethanol 
(95%). Carbomers do not dissolve but merely swell to a remarkable extent, 
since they are three-dimensionally crosslinked microgels.  
 Viscosity (dynamic): Carbomers disperse in water to form acidic colloidal 
dispersions of low viscosity that, when neutralized, produce highly viscous 
gels Carbomer powders should first be dispersed into vigorously stirred water, 
taking care to avoid the formation of indispersible agglomerates, then 
neutralized by the addition of a base. 
10. Method of Manufacture: 
 Carbomers are synthetic, high-molecular-weight, crosslinked polymersof 
acrylic acid. These acrylic acid polymers are crosslinkedwith allyl sucrose or allyl 
pentaerythritol. The polymerization solvent used previously was benzene; however, 
some of the newer commercially available grades of carbomer are manufactured using 
either ethyl acetate or a cyclohexane–ethyl acetate cosolvent mixture. The Carbopol  
and Carbopol Ultrez polymers areproduced in the cosolvent mixture with a 
proprietary polymerization aid. 
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11. Stability and Storage Conditions: 
     Carbomers are stable, hygroscopic materials that may be heated at 
temperatures below 104°C for up to 2 hours without affecting their thickening 
efficiency. However, exposure to excessive temperatures can result in 
discoloration and reduced stability.  
2.3.2. Polyethylene glycol 400:                      ( Raymond C. R., 2003) 
1. Nonproprietary Names: 
 
 BP: Macrogols 
 JP: Macrogol 400 
 PhEur: Macrogols 
 USP-NF: Polyethylene Glycol 
2. Synonyms: 
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; macrogola; PEG; 
Pluriol E; polyoxyethylene glycol. 
3. Chemical Name and CAS Registry Number:  
   a-Hydro-o-hydroxypoly(oxy- 1,2-ethanediyl) [25322-68-3] 
4. Empirical Formula                              : H(OCH2CH2)nOH 
5. Molecular Weight                               : 380–420 
6. Structural formula: 
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7. Functional Category: 
Ointment base; plasticizer; solvent; suppository base; tablet and 
capsule lubricant. 
8. Description: 
 Appearance: Clear, colorless or slightly yellow-colored, viscous liquids.tic 
odor and a warm. 
 Odor: Slight but characteristic odor 
 Taste:  Bitter, slightly burning taste. 
9. Typical properties: 
 
 Freezing point          :  4–8 ºC 
 Flash point           :  238 ºC 
 Density           :  1.11–1.14 g/cm3 at 25 ºC  
 Moisture content              : Liquid polyethylene glycols are very hygroscopic, 
although hygroscopicity decreases with increasing molecular weight.  
 Viscosity (mPas)          :  90.0 (25 ºC); 7.4 (99 ºC)  
 Solubility:  
        All grades of polyethylene glycol are soluble in water and miscible in all 
proportions with other polyethylene glycols (after melting, if necessary). 
Aqueous solutions of highermolecular-weight grades may form gels. Liquid  
polyethylene glycols are soluble in acetone, alcohols, benzene, glycerin, and 
glycols. 
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10. Method of Manufacture: 
       Polyethylene glycol polymers are formed by the reaction of ethylene oxide and 
water under pressure in the presence of a catalyst. 
11. Applications in Pharmaceutical Formulation or Technology: 
Polyethylene glycols (PEGs) are widely used in a variety of pharmaceutical 
formulations, including parenteral, topical, ophthalmic, oral, and rectal preparations. 
Polyethylene glycol has been used experimentally in biodegradable polymeric 
matrices used in controlled-release systems. Aqueous polyethylene glycol solutions 
can be used either as suspending agents or to adjust the viscosity and consistency of 
other suspending vehicles. When used in conjunction with other emulsifiers, 
polyethylene glycols can act as emulsion stabilizers. 
12. Stability and Storage Conditions:  
Polyethylene glycols are chemically stable in air and in solution, although grades 
with a molecular weight less than 2000 are hygroscopic. Polyethylene glycols do not 
support microbial growth, and they do not become rancid. 
Polyethylene glycols and aqueous polyethylene glycol solution can be sterilized 
by autoclaving, filtration, or gamma irradiation. 
 
2.3.3. PLURONIC  F-127 (Poloxamer 407):                  (Raymond C Rowe., 2003) 
1. Nonproprietary Names: 
 BP: Poloxamers 
 PhEur: Poloxamers 
 USP-NF: Poloxa 
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2. Synonyms :  
  Lutrol; Monolan; Pluronic; poloxalkol; poloxamera; polyethylene-propylene 
glycol copolymer; polyoxyethylene-polyoxypropylene copolymer; Supronic; 
Synperonic. 
3. Chemical Name and CAS Registry Number :  
a-Hydro-o-hydroxypoly(oxyethylene)poly(oxypropylene) poly-(oxyethylene) 
block copolymer [9003-11-6]. 
4. Empirical Formula           : C21H27NO.HCl 
5. Molecular Weight               : 345.91 
6. Structural Formula : 
 
 
7. Functional Category: 
             Dispersing agent; emulsifying agent; solubilizing agent; tablet 
lubricant; wetting agent. 
8. Applications in Pharmaceutical Formulation or Technology: 
       Poloxamers are nonionic polyoxyethylene–polyoxypropylene copolymers 
used primarily in pharmaceutical formulations as emulsifying or solubilizing agents. 
Poloxamers are used as emulsifying agents in intravenous fat emulsions, and as 
solubilizing and stabilizing agents to maintain the clarity of elixirs and syrups. 
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Poloxamers may also be used as wetting agents; in ointments, suppository bases, gels 
and as tablet binders and coatings. 
9. Description: 
 Color: White, waxy, free-flowing prilled granules, or as cast solids. 
 Odor: odorless. 
 Taste: tasteless.  
10. Typical properties: 
  Acidity/alkalinity: pH = 5.0–7.4 for a 2.5% w/v aqueous solution 
 Flash point:  260 ºC 
 Flowability:  Solid poloxamers are free flowing. 
 Melting point: 52–57 ºC 
 Moisture content:  Poloxamers generally contain less than 0.5% w/w water 
and are hygroscopic only at relative humidity greater than 80%. 
 Solubility of Pluronic F127: 
           Table 2.3: Table indicating solubility of pluronic F127                           
       S.No Solvent Solubility 
 
 
1 
 
 
Ethanol 
(95%) 
 
Freely soluble 
 
 
2 
 
Propan-2-ol 
 
Freely soluble 
 
 
3 
 
 
Water 
 
Freely soluble 
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10. Method of Manufacture:  
         Poloxamer polymers are prepared by reacting propylene oxide with propylene 
glycol to form polyoxypropylene glycol. Ethylene oxide is then added to form the 
block copolymer. 
11. Stability and Storage Conditions:  
       Poloxamers are stable materials. Aqueous solutions are stable in the presence of 
acids, alkalis, and metal ions. However, aqueous solutions support mold growth. 
       The bulk material should be stored in a well-closed container in a cool, dry place. 
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3. AIM AND OBJECTIVE 
 
The nasal mucosa has been considered as a potential administration route to 
achieve faster and higher level of drug absorption. This is due to the large surface 
area, porous endothelial membrane, and high total blood flow. Recently focus has 
been made on the nasal mucosa as an alternate route to achieve faster and higher 
absorption. 
Rizatriptan Benzoate is 5HT1B/1D receptor agonist with an oral bioavailability 
of 40% and half life of 2-3 h. To increase the bioavailability and brain tissue 
deposition of antimigraine therapy, Intranasal delivery system were developed. 
Intranasal administration offers a practical noninvasive alternative mode for drug 
targeting to the brain. 
Nasal delivery of drugs offers many advantages over other delivery routes 
still posses some drawbacks like nasal mucociliary clearance which results in reduced 
absorption of drug. Several strategies were tested to improve nasal absorption of drug. 
To improve the nasal absorption of drug it is necessary to increase the nasal residence 
time. One method to lengthen nasal residence time has been to include a bioadhesive 
in the formulation. The use of bioadhesive polymers can increase nasal absorption of 
drugs with several ways such as increasing the residence time of drug in the nasal 
cavity. Carbopol derivatives are bioadhesive polymers used in attempt to formulate 
mucoadhesive drug delivery system for application to nasal mucosa. 
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Poloxamers or pluronics are triblock copolymers which form micelles at low 
concentration and clear, thermoreversible gel at high concentrations.The concentrated 
solutions (20-30%) are transformed from low viscosity transparent solutions at 5
0 
C to 
solid gel on heating to body temperature. By modulating the gelation temperature of 
different PF 127 solutions, liquid bases for nasal nasal use can be formulated that 
form a gel in nasal cavity at body temperature resulting in enhancement of residence 
time in the nasal cavity. 
Possible strategy used to decrease the mucociliary clearance by use of 
gel/mucoadhesive formulation to prolong nasal residence time. Neverthless, the most 
prominent advantage of the in situ gel over the silent gel is that is fluid like prior to 
contact with nasal mucosa, a feature that offers the convenience of administration for 
patients since it can be easily instilled as a drop allowing accurate drug dosing. 
 Hence, the objective of this study was to develop temperature induced 
mucoadhesive in situ gel formulation for Rizatriptan Benzoate by using 3² full 
factorial design in order to achieve prolonged action and controlled release and direct 
delivery by nasal route. This may give patient friendly, needle free dosage form 
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                                                   4. PLAN OF WORK 
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5. MATERIALS AND EQUIPMENTS 
 
5.1. MATERIALS USED: 
 
Table 5.1: List of Drug and Polymers with source  
 
S.No. Ingredients Supplier 
1 Rizatriptan Benzoate Strides Arco lab, Bangalore. 
2 Carbopol 974P Loba Chemie Pvt. Ltd., Mumbai. 
3 Poly ethylene glycol 400 S D fine-chem limited, Mumbai. 
4 Pluronic F127 
S D fine-chem limited, Mumbai. 
5 Potassium dihydrogen phosphate Qualigens fine chemicals, Mumbai 
6 Sodium hydroxide S D fine-chem limited, Mumbai 
8 Dialysis bag Himedia labaratories, Mumbai. 
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5.2.  EQUIPMENTS USED: 
 
Table 5.2: List of Equipments with model/make 
 
S.No Equipments Model/ Make 
1. Electronic Balance Shimadzu BL-220H 
2. Clarity Test Apparatus Labtech 
2. Chemical Balance Shimadzu BL-220H 
3. pH Meter LI120 pHmeter, ELICO LTD 
4. Humidity Chamber Labtech 
5. UV Visible Spectrophotometer Shimadzu-1700 Pharmaspec  
UV-visible spectrophotometer, Elico 
6. FTIR Spectrophotometer Shimadzu FTIR-801 spectrophotometer 
7. Differential Scanning Calorimeter Shimadzu  DSC W70 
8. Melting Point Apparatus Guna enterprises, Chennai 
9. Viscometer Brookfield DV-11 + PRO Viscometer 
10. Franz Diffusion Cell Apparatus Scientific glass, Coimbatore 
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6. PREFORMULATION STUDY 
 
6.1. Identification of Drug: 
 
The preliminary studies were carried out by testing of different physical and 
chemical properties of drug as follows.  
 
6.1.1. Organoleptic properties:                                 (Lachmann L., et al., 1991)                                      
            The Organoleptic properties like physical state, color, odor etc., of the drug 
was reported with help of the descriptive terminology. It helps to identify the       
drug. 
 
6.1.2. Determination of Melting point:                                             (IP., 2007)                                                                                                                                                                    
 
It is the easy way to identify the drug. The melting point of Rizatriptan 
Benzoate was tested by use of a laboratory melting point apparatus with a procedure 
given in the Indian Pharmacopeia 2007. 
 
6.1.3. Solubility study:                                                                                (IP., 2007) 
 
The solubility of Rizatriptan Benzoate was determined by micropipette 
method in various solvents in order to meet the official standards. The solubility of 
drug was recorded by using various descriptive terminology specified in Indian 
pharmacopoeia, 2007. 
    The general description of solubility as per Indian Pharmacopoeia was listed 
out in the Table 6.1. 
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                Table 6.1: Description of solubility 
Descriptive term Parts of solvent required for 1 part of 
solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1,000 
Very slightly soluble From 1,000 to 10,000 
Practically insoluble Greater than or equal to 10,000 
 
6.1.4. FTIR spectroscopy:                
                                   (Skoog D.A., et al. (1996); Robert M. Silverstein., et al., 2003) 
   The infrared spectrum was generally used as an identification parameter to 
know the chemical structure of drugs. For the FTIR spectrum of Rizatripan Benzoate 
FTIR spectrophotometer was used.  
A small quantity of sample was mixed with sufficient potassium bromide and 
compressed into a pellet by applying a 10 tons pressure with help of a hand operated 
press. This pellet was kept in a sample holder and scanned from 4000 to 400 cm
-1
. 
The absorption maximums in spectrum obtained with the substance being examined 
correspond in position and relative intensity to those in the reference spectrum.  
 
 
 
 
 
Nasal In Situ Gel of Rizatriptan Benzoate                      Preformulation Study 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 87 
6.1.5. UV Spectrophotometric Study:  
6.1.5.1. Determination of λ max:            (Prashant S.Khairnar. et al., 2011) 
                
The absorption maximum of the standard solution was scanned between 200-
400 nm regions on Shimadzu-1700 Pharmaspec UV-visible spectrophotometer. The 
absorption maximum obtained with the substance being examined corresponds in 
position and relative intensity to those in the reference spectrum. 
 
6.1.5.2. Development of standard curve of Rizatriptan Benzoate in Ditilled water: 
 Preparation of stock solution: 
Accurately weighed 10 mg of Rizatriptan Benzoate was dissolved in 100 mL 
of distilled water to get the concentration of 100 µg/mL.   
 
 Procedure: 
 From the stock solution, aliquots of 1, 2, 3, 4 and 5 mL were transferred to 50 
mL volumetric flasks and final volume was made to 50 mL with distilled water to get 
2 to 10 µg/mL. Absorbance values of these solutions were measured against blank 
(methanol) at 224.4 nm using UV-visible spectrophotometer. 
6.1.5.3. Development of standard curve of Rizatriptan Benzoate:   
   Preparation of phosphate buffer  pH 6.4: 
   Phosphate buffer  pH 6.4 was prepared according to I.P. 2007. A quantity of 
50 mL of 0.2 M potassium dihydrogen phosphate in a 200 mL volumetric flask and 
added 11.6 mL of 0.2 M sodium hydroxide was diluted with fresh distilled water to 
produce 200 mL. 
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    Preparation of stock solution of Rizatriptan Benzoate Buffer pH 6.4 
solution: 
   Accurately weighed 10 mg of Rizatriptan Benzoate was dissolved in little 
quantity of phosphate buffer  solution pH 6.4 and volume was adjusted to 100 
mL with the same to prepare standard solution having concentration of 100 
µg/ mL.  
 
    Procedure: 
    From the stock solution, aliquots of 2, 4, 6, 8 and 10 mL were transferred to 
50 mL volumetric flasks and final volume was made to 10 mL with pH 6.4 
phosphate buffer  to get 2 to 10 µg/mL. Absorbance values of these solutions 
were measured against blank (phosphate buffer pH 6.4) at 224.4 nm using 
UV-visible spectrophotometer.  
6.1.6. Quantification of Rizatriptan Benzoate:   
                                                          (Achariya Sasmita Kumari. et al., (2010) 
Accurately weighed 10 mg of Rizatriptan Benzoate was dissolved in little quantity of 
phosphate buffer 6.4 and volume was adjusted to 100 mL with the same to prepare 
standard solution having concentration of 100 µg/mL. From the above solution, 
aliquots of 5 mL were transferred to 50 mL volumetric flasks and final volume was 
made to 50 mL with phosphate buffer 6.4. Absorbance values of these solutions were 
measured against blank (phosphate buffer 6.4) at 225.5 nm using Shimadzu-1700 
Pharmaspec UV-visible spectrophotometer. The percentage purity of drug was 
calculated by using calibration graph method (least square method).  
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6.2. Drug – Polymers Intraction Study:                                         
6.2.1. Fourier Transforms Infra-Red (FTIR) Spectroscopy: 
                             (Skoog D.A., et al. (1996); Robert M. Silverstein., et al., 2003) 
FTIR study was carried out to check identity of drug. Infrared spectrum of 
Metoprolol tartrate was determined on Fourier transform Infrared Spectrophotometer 
using KBr dispersion method. The base line correction was done using dried 
potassium bromide. Then the spectrum of dried mixture of drug and potassium 
bromide was run followed by drug by using FTIR spectrophotometer. The absorption 
maximums in spectrum obtained with the substance being examined correspond in 
position and relative intensity to those in the reference spectrum.
                                        
 
6.2.2. Differential Scanning Calorimetry (DSC) Analysis: 
                                                                                                   (IP., 2007)
 
The proper design and formulation of a dosage form requires consideration of 
the physical, chemical and biological characteristics of all drug substances and 
excipients to be used in the fabricating the product. Each polymer used in the 
formulations was blended with the drug levels that are realistic with respect to the 
final dosage form. Each polymer was thoroughly blended with drug to increase drug- 
polymer molecular contacts to accelerate the reactions if possible. 
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7.  FORMULATION OF  MUCOADHESIVE NASAL IN SITU GELS 
 
7.1. Designing the formula:                                    (Varsha gaikwad., et al., 2010) 
 In situ gels were designed by 3
2
 full factorial design to study the interaction 
variables of formulation on characterization of In situ gels. Amount of carbopol 974P 
and PEG 400 were selected as independent variable. Amount of Rizatriptan Benzoate 
(100mg) were kept constant. The variables and the level of each factor were shown in 
table 7.1.  
Table 7.1:   Variables in 3
2
 full factorial design 
 
Each row identifies an experiment and each row provides a result (response). 
The levels of factors studied were chosen that the irrelative difference was adequate to 
have a measurable effect on response, along with the information that the selected 
levels are within practical use. The formulation of the factorial design is represented 
in table 7.2. 
 
Independent  variable 
factors 
                                
                               Levels used 
 
Lower (-1) 
 
Middle (0) 
 
Upper (+1) 
 
Carbopol 974P  (X1) % 
 
0.25 
 
 
0.5 
 
 
0.75 
 
 
PEG 400 (X2) % 
 
6 
 
8 
 
10 
 
                   Amount of drug used was 100mg in all formulation 
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              Table 7.2:  Designing the formulation with a 3
2
 full factorial design   
 
S.NO 
 
Formulation 
code 
 
Carbopol 974P  (X1) 
% 
 
PEG 400 
(X2)% 
1 MG1 -1 (0.25) -1 (6) 
2 MG2 -1 (0.25) 0 (8) 
3 MG3 -1 (0.25) +1 (10) 
4 MG4 0 (0.5) -1 (6) 
5 MG5 0 (0.5) 0 (8) 
6 MG6 0 (0.5) +1 (10) 
7 MG7 +1 (0.75) -1 (6) 
8 MG8 +1 (0.75) 0 (8) 
9 MG9 +1 (0.75) +1 (10) 
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Table 7.3: Composition of Mucoadhesive Nasal In situ Gels: 
 
INGREDIENTS                   
(%) 
 
MG1 
 
MG2 
 
MG3 
 
MG4 
 
MG5 
 
MG6 
 
MG7 
 
MG8 
 
MG9 
 
Drug(Rizatriptan 
Benzoate) 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
Carbopol 
974P 
 
0.25 
 
0.25 
 
0.25 
 
0.5 
 
0.5 
 
0.5 
 
0.75 
 
0.75 
 
0.75 
 
Poly Ethylene 
Glycol 400 
 
6 
 
8 
 
10 
 
6 
 
8 
 
10 
 
6 
 
8 
 
10 
 
Pluronic 
F127 
 
18 
 
18 
 
18 
 
18 
 
18 
 
18 
 
18 
 
18 
 
18 
 
Distilled 
water(Q.S.)ml 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
PREPARATION OF MUCOADHESIVE NASAL IN SITU GELS: 
                                                      (Varsha Gaikwad., et al., 2010) 
Thermoreversible pluronic insitu gels were prepared by cold technique. 
To the 1%, solution of drug in distilled water, PEG 400 was added in the 
quantity of 6, 8, and 10% w/v. To this Carbopol 974 P was added in qty i.e. 0.5% w/v.  
This solution was then stirred until Carbopol 974P completely dissolves in it. After 
the complete dissolving of this Carbopol 974P, Pluronic F127 (Poloxamer 407) was 
added to it. 
Pluronic F127, 18% w/v used as base throughout preparations. This resulting 
formulation was then kept at 4
 0
 C overnight until clear gel obtained. 
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8. EVALUATION OF MUCOADHESIVE NASAL IN SITU GELS 
 
8.1. Clarity:                                                              (Jitendra V. Shinde.,  et al.,2008) 
 The clarity of various formulations was determined by visual inspection under 
black and white background by using clarity test apparatus and it was graded as 
follows; 
Turbid +, Clear ++, Very clear (glassy):+++. 
8.2. Measurement of gelation temperature (T1) :                
                        (Jyothivarthan Jaiswal, et al., 2012; Varsha gaikwad., et al., 2010) 
        It was determined by using method described by Miller and Donovan technique. 
A 2 mL aliquot of gel was transferred to a test tube, immersed in a water bath. The 
temperature of water bath was increased slowly and left to equilibrate for 5 min at 
each new setting. The sample was then examined for gelation, which was said to have 
occurred when the meniscus would no longer moves upon tilting through 90
o 
C. 
8.3 Measurement of gel meting temperature (T2):    (Varsha gaikwad., et al., 2010)                                                       
      After attaining the temperature T1, further heating of gel causes liquification of 
gel and form viscous liquid and it starts flowing, this temperature is noted as T2 i.e. 
gel melting temperature.It is a critical temperature when the gel starts flowing upon 
tilting test tube through 90
 o
C. 
8.4. Determination of pH:                                 (Jitendra V. Shind., et al., 2008)                                                    
       1 mL quantity of each formulation was transferred to the 10 mL volumetric flask 
and diluted by using distlled water to make 10 mL.  pH of resulting solution was 
determined by using digital pH meter (LI120 pH meter, ELICO LTD) 
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8.5. Drug content:                                         (Jyothivarthan Jaiswa., et al., 2012)  
        1 mL of formulation was taken in 10 mL volumetric flask, diluted with distilled 
water and volume adjusted to 10 mL. 1 mL quantity from this solution was again 
diluted with 10 mL of distilled water. Finally the absorbance of prepared solution was 
measured at 225.5 nm by using UV visible spectrophotometer. 
8.6.   Determination of Mucoadhesive strength:   (Jitendra V. Shinde., et al., 2008)               
        The mucoadhesive strength of each formulation was determined by measuring 
the force required to detach the formulation from goat nasal mucosal tissue by using a 
modified chemical balance.  
       A section of nasal mucosa was cut from the goat’s nasal cavity and mucosal side 
was instantly fixed into each glass vial using a rubber band. The vials with nasal 
mucosa were stored at 37°C for 5 minutes. Then next vial with a section of mucosa 
was connected to the balance in inverted position while first vial was placed on a 
height adjustable pan. Fixed amount of sample of each formulation were placed onto 
the nasal mucosa of first vial. Then the height of second vial was adjusted so that 
mucosal surfaces of both vials come in intimate contact. Two minutes contact time 
was given to ensure intimate contact between tissues and the sample. Then weight 
was increased in the pan until vials got detached. 
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                                  Fig 8.1: Mucoadhesion test assembly 
The bioadhesive force, expressed as the detachment stress in dyne/cm
2
, was 
determined from the minimal weights that detached the tissues from the surface for 
each formulation using the following equation.  
 
 
                       Where, m =Weight required for detachment of two vials in gm  
                                    g = Acceleration due to gravity [980cm/s
2
]  
                                    A = Area of tissue exposed  
The nasal mucosa was changed for each measurement. Measurements were 
repeated three times for each of the gel preparations. 
Detachment stress (dyne/cm
2
) = m x g /A  
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8.7.      Measurement of Viscosity:
          
   (Varsha gaikwad., et al., 2010)          
 
                                                     
  
The viscosity measurements were carried out by using Brookfield  DV-11 Pro 
viscometer. The gel sample was placed in small sample adaptor. Temperature was 
increased in the range of 20
 0
C – 34 0C, using a water circulation jacket. The 
temperature sensing probe was lowered in gel and temperature of gel was recorded. 
Viscosity at various temperatures was recorded. 
8.8. In-vitro Drug Permeation Studies:           (Vijaya Kumar., et al., 2012)           
     Drug release from gel was tested with Franz diffusion cell, using dialysis 
membrane (mol.wt.12000-14000) with permeation area of 2.545 cm². 25 mL of 
phosphate buffer 6.4 was added to the acceptor chamber. Gel containing drug 
equivalent to 10 mg was placed in donor compartment. At predetermined time points, 
1 mL sample were withdrawn from the acceptor compartment, replacing the sample 
volume with phosphate buffer buffer pH 6.4 after each sampling for a period of 5 h. 
The samples were suitably diluted and measured spectrophotometrically at 225.5 nm. 
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                              Fig 8.2: In-vitro permeation assembly 
 8.9. Histopathological Studies Of Optimized Formulation:  (Jaiswal., et al., 2012) 
 Fresh nasal tissue was removed from the nasal cavity of goat. The tissue was 
inserted in the Franz  diffusion cell. Phosphate buffer (pH6.4) was then added to the 
acceptor chamber. Then gel was applied to the mucosa and left for the 12 h. Another 
control mucosa was also setup without using the drug. After 12 h each piece of 
mucosa was carefully removed from the diffusion chamber, rinsed with phosphate 
buffer. The mucosa sample was then fixed in the 1% formaldehyde solution for 6h. 
The samples were then incubated in methyl benzoate for 24 h in order to soften the 
material. The samples were immersed first into benzene:paraplast (1:1) mixture, and 
then into pure paraplast for 6 h in a vacuum oven and embedded in paraplast. The 
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blocks were cut in sections of 5-6μm in thickness with a rotary microtom. The section 
was stained for the light microscope examination.  
 8.10. Kinetic Modeling of Drug Permeation:    
                                                              (Brahmankar D.M. and Jaiswal S.B., 2006)
 
 To study the release kinetics of in-vitro drug release, data was applied to kinetic 
models such as zero order, first order, Higuchi and Korsmeyer- Peppas.
 
 Zero order: 
 
Where K0 - is the zero-order rate constant expressed in units of 
concentration/time   
                          t -is the time in hrs. 
 First order: 
 
Where   C0 - is the initial concentration of drug, 
   
                         K - is the first order constant 
                 t - is the time in hrs.  
 Higuchi: 
 
                    Where   Qt - is the amount of the release drug in time t, 
                                                                                                    
LogC = LogC0 – Kt / 2.303                                                                             
Qt = Kt
1/2
                                                                                                          
C = K0t                                                                                                               
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                  K- is the kinetic constant and  
                           t- is time in hrs. 
 Korsmeyer Peppas: 
 
       Where   Mt - represents amount of the released drug at time t,  
                    M∞- is the overall amount of the drug (whole dose) released after 12 hrs  
                    K- is the diffusional characteristic of drug/ polymer system constant  
                    n- is a diffusional exponent that characterizes the mechanism of release 
of drug.  
The value of n indicates the drug release mechanism related to the geometrical 
shape of the delivery system, if the exponent n = 0.5, then the drug release mechanism 
is Fickian diffusion. If n < 0.5 the mechanism is quasi-Fickian diffusion, and  0.5 < n 
< 1.0, then it is non-Fickian or anomalous diffusion and when n = 1.0 mechanism is 
non Fickian case II diffusion, n> 1.0 mechanism is non Fickian super case II. 
8.11. Stability studies:           (Manavalan R and Ramasamy S., 1991) 
 
         Stability is defined as the capacity of a drug substance or drug product to remain 
within established specifications to maintain its identity, strength, quality, and purity 
throughout the retest or expiration dating periods (FDA, 1998). 
Stability of pharmaceutical preparation can be defined as the capability of 
particular formulation (dosage form) in a specific container/closure system to remain 
within its physical, chemical, microbiological, therapeutic and toxicology 
specifications throughout its shelf life. 
Mt / M∞ = Kt n                                                                                                                                                                                                    
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The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted. The International Conference on Harmonization (ICH) 
Guidelines titled “Stability testing of New Drug Substances and Products” describes 
the stability test requirements for drug registration application in the European Union, 
Japan and the States of America. 
ICH specifies the length of study and storage conditions 
 Long-Term Testing: 25°C ± 2°C at 60% RH ± 5% for 12 Months 
 Accelerated Testing: 40°C ±2°C at 75% RH ± 5% for 6 Months 
Procedure:                                           (Zheng Cai., et al., 2011) 
 
 The study was carried out to observe the effect of temperature on optimized 
formulation (MG4). Stability studies were carried out at  40°C ±2°C at 75% RH ± 5% 
for the formulation MG4 for 3 months. A quantity of Rizatriptan Benzoate in situ gel 
in cillin bottles were stored in a dessicator containing a saturated solution of sodium 
chloride, which provided a relative humidity of 75 ±5%. The dessicator was plaed in a 
hot air oven maintained at 40
0
C ± 2
0
C, and the samples were withdrawn at 1, 2 and 3 
months . 
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 The samples were analyzed for its parameters such as, 
 Clarity 
 Gelatiom Temperature (T1) 
 Gel melting Temperature (T2) 
 pH 
 Drug content 
 In-vitro drug permeation study 
 
 
  
.  
  
 
 
Results 
And 
Discussion 
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9. RESULTS AND DISCUSSION 
 
9.1. Identification of Drug: 
  
9.1.1. Organoleptic Properties:
 
Colour           :  Off white crystalline solid 
Odour            :  Characteristic odour 
 9.1.2. Determination of Melting Point: 
Melting point of Rizatriptan Benzoate was found to be 179
 
ºC. 
The official melting point range for Rizatriptan Benzoate is between 178-
180°C. Hence, results were complied the limits specified in official Book. 
9.1.3. Solubility Study:
 
Table 9.1: The solubility of Rizatriptan Benzoate in various solvents              
 
 
S.No.  
 
 
Name of solvent 
 
Solubility 
 
Parts of solvent required 
for 1 part of solute 
1 0.1 N sodium 
hydroxide 
Freely soluble 10 
 
2 Distilled water Soluble 20 
 
3 Ehanol Slightly soluble 100 
 
4 Methanol Soluble 20 
 
5 0.1 N HCl Soluble 30 
 
6 Phosphate buffer 
pH 6.4 
Soluble 10 
 
7 PEG 400 Soluble 30 
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9.1.4. FTIR spectroscopy: 
The FTIR spectrum of Rizatriptan Benzoate was shown in Figure 
9.1 and the interpretations of IR frequencies were showed in Table 9.2. 
 
 
                                        Fig.9.1: FTIR spectrum of Rizatriptan Benzoate 
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Table 9.2: Characteristic Frequencies in FTIR spectrum of Rizatriptan 
Benzoate 
 
S.No. Transition IR Range (cm
-1
) 
Absorption wave 
number of Rizatriptan 
Benzoate (cm
-1
) 
1 C-H bending 4000-3980 3857.29 
2 O-H stretching 3840-2920 3714.69 
3 C=C bending 2400-2100 2243.22 
4 C=O stretching 1730-1600 1702.53 
5 C=C stretching 1680-1500 1655.86 
6 C-H bending 1480-1300 1458.99 
7 C-O stretching 1350-1200 1294.21 
8 C-C stretching 995-985 959.15 
9 C-H bending 900-860 888.63 
10 C-C bending 760-685 673.66 
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Interpretation of FTIR Spectrum: 
Major functional groups present in Rizatriptan Benzoate show 
characteristic peaks in IR spectrum. Table 9.2 shows peaks observed at 
different wave numbers and the functional group associated with these 
peaks.
 
The major peaks are identical to functional group of Rizatriptan 
Benzoate. Hence, the sample was confirmed as Rizatriptan benzoate. 
9.1.5. UV Spectrophotometric Study:
 
 The absorption maximum for Rizatriptan Benzoate in distilled 
water was found to be 225.5 nm. 
 
 
Fig. 9.2: λmax of Rizatriptan Benzoate in distilled water 
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 The absorption maximum for Rizatriptan Benzoate in phosphate 
buffer  pH
 
6.4 was found to be  225.5 nm 
 
              Fig. 9.3: λmax of Rizatriptan Benzoate in Phosphate buffer pH
 
6.4 
9.1.6. Calibration curve of Rizatriptan Benzoate in distilled water: 
UV absorption spectrum of Rizatriptan benzoate in distilled water 
showed λ max at 225.5 nm. Absorbance obtained for various 
concentrations of Rizatriptan Benzoate in distilled water were given in 
Table 9.3. The graph of absorbance vs concentration for Rizatriptan 
Benzoate was found to be linear in the concentration range of 2-10 μg 
/mL. The drug obeys Beer- Lambert’s law in the range of 2-10 μg /mL. 
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Table 9.3: Data of concentration and absorbance for Rizatriptan  
Benzoate in distilled water. 
 
 
 
S.No. Concentration 
(µg/mL) 
Absorbance 
1 0 0.0000 
2 2 0.195 
3 4 0.377 
4 6 0.567 
5 8 0.745 
6 10 0.926 
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       Fig. 9.4: Standard graph of Rizatriptan Benzoate in Distilled Water  
 
                         
                     Table 9.4:  Data for Calibration Curve Parameters 
 
S.No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope (m) 0.0915 
3 Intercept (c) 0.013 
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9.1.7. Calibration Curve of Rizatriptan Benzoate in Phosphate buffer 
pH 6.4: 
 
UV absorption spectrum of Rizatriptan Benzoate in phosphate 
buffer  pH 6.4 showed λ max at 225.5 nm. Absorbance obtained for various 
concentrations of Rizatriptan Benzoate in phosphate buffer pH 6.4 were 
given in Table 9.5.  
 
The graph of absorbance Vs concentration for Rizatriptan 
Benzoate was found to be linear in the concentration range of 2-10 μg 
/mL. The drug obeys Beer- Lambert’s law in the range of 2-10 μg /mL. 
 
 
Table 9.5: Data of concentration and absorbance for Rizatriptan 
Benzoate in Phosphate buffer pH
 
6.4. 
S.No. Concentration 
(µg/mL) 
Absorbance 
1 0 0.0000 
2 2 0.189 
3 4 0.386 
4 6 0.571 
5 8 0.755 
6 10 0.936 
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 Fig. 9.5: Standard graph of Rizatriptan Benzoate in Phosphate Buffer  
pH 
 
6.4.                
                   
                  Table 9.6:  Data for Calibration Curve Parameters 
S.No. Parameters  Values  
1 Correlation coefficient (r) 0.9997 
2 Slope (m) 0.0931 
3 Intercept (c) 0.0085 
 
9.1.8. Quantification of Rizatriptan Benzoate 
The percentage purity of drug was calculated by using calibration 
graph method. The values were recorded in the table 9.7. 
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                   Table 9.7:  Quantification  of  Rizatriptan  Benzoate 
  
 
 
 
 
 
 
 
 
The official percentage purity of Rizatriptan Benzoate is not less 
than 98% and not more than 102%. So, it can be declared as pure drug. 
The percentage purity of raw material Rizatriptan Benzoate was found to 
be 100.13±0.38. Hence, the sample declared as pure. 
 
 
 
 
 
 
 
S.No. Percentage purity 
(%) 
Average percentage 
purity (%) 
1 99.78  
100.13±0.38 
2 100.01 
3 100.53 
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 9.2. Drug - Polymers Interaction Studies. 
9.2.1. Fourier Transforms Infra-Red (FTIR) Spectroscopy Study. 
 
                           
Fig. 9.6: FTIR spectrum of Rizatriptan Benzoate  
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         Fig. 9.7: FTIR spectrum of Rizatriptan Benzoate and carbopol 974P 
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                 Fig. 9.8: FTIR spectrum of Rizatriptan Benzoate and PEG 400 
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      Fig. 9.9: FTIR spectrum of Rizatriptan Benzoate and Pluronic F127 
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Table 9.8: Major peak observed in FTIR spectrum of pure          
Rizatriptan Benzoate and Rizatriptan Benzoate with polymers carbopol 
974P, PEG 400, Pluronic F127. 
 
  
 
 
 
 
S.NO 
 
Wave 
No. 
(cm
-1
) 
 
Functional 
group 
 
Peak observed (Yes/No) 
 
Drug 
 
Carbopol 
974P 
 
PEG 
400 
 
Pluronic 
F127 
1 3857.29 C-H bending Yes Yes Yes Yes 
2 3714.69 O-H stretching   Yes Yes Yes Yes 
3 2243.22 C=C bending Yes Yes Yes Yes 
4 1702.53 C=O stretching Yes Yes Yes Yes 
5 1655.86 C=C stretching  Yes Yes Yes Yes 
6 1458.99 C-H bending  Yes Yes Yes Yes 
7 1294.21 C-O stretching Yes Yes Yes Yes 
8 959.15 C-C stretching Yes Yes Yes Yes 
9 888.63 C-H bending Yes Yes Yes Yes 
10 673.66 C-C bending Yes Yes Yes Yes 
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From the spectral analysis it was found that FTIR spectrum of 
Rizatriptan Benzoate with Polymers Carbopol 974P, PEG 400, Pluronic 
F127 showed all charecteristics peaks in combination with no significant 
changes as shown in fig.9.6 to 9.9. Therefore, it could indicate that there 
was no incompatability between drug and polymers. 
9.2.2. Differential Scanning Calorimetry (DSC) Analysis: 
 The compatability and interactions between drug and polymers 
were cheked using DSC; results obtained were shown in Fig. 9.10 and 
9.11. 
 
                                Fig. 9.10: DSC Thermogram of Rizatriptan Benzoate 
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 Fig. 9.11: DSC Thermogram of Rizatriptan Benzoate and Carbopol 974P 
+ PEG 400 + Pluronic F127 
                        Table 9.9: Data for DSC Thermogram Parameters 
S. 
No. 
DSC thermogram 
sample 
Onset 
temperature (°C) 
Peak 
temperature 
(°C) 
1 Rizatriptan Benzoate 183.87 186.53 
2 Rizatriptan Benzoate + 
Carbopol974P + PEG 
400 + Pluronic F127 
182.05 184.25 
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 According to Table 9.9, DSC thermogram showed that there was 
no major difference in onset temperature and peak temperature when 
compared with pure drug’s thermogram. No interaction was found 
between drug and polymers. The DSC studies suggest that polymers 
carbopol 974P, PEG 400, Pluronic F127 and the drug Rizatriptan 
Benzoate do not interact to form any chemical entity but remain as a 
mixture. Therefore, it could indicate that there was no incompatability 
between drug and polymers. 
9.3. Evaluation of Mucoadhesive Nasal In Situ Gels: 
9.3.1 Clarity: 
The clarity of nine formulations of Rizatriptan Benzoate 
Mucoadhesive Nasal In Situ Gels were recorded in Table 9.10.  
The clarity of various formulations were determined by visual inspection 
under black and white background. All the prepared formulations were 
found to be clear (+) and very clear (+++ glassy). The very clear 
transparent solution was found to be MG4 with the grade of +++ under 
the visual inspection of both black and white background.
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                       Table 9.10: Clarity of Mucoadhesive Nasal In Situ Gels 
 
S.NO 
 
FORMULATION 
CODE 
 
VISUAL APPEARANCE 
 
BLACK  
BACKGROUND 
 
WHITE 
BACKGROUND 
 
1 
 
MG1 
 
++ 
 
++ 
 
2 
 
MG2 
 
++ 
 
++ 
 
3 
 
MG3 
 
++ 
 
+++ 
 
4 
 
MG4 
 
+++ 
 
+++ 
 
5 
 
MG5 
 
++ 
 
+++ 
 
6 
 
MG6 
 
++ 
 
++ 
 
7 
 
MG7 
 
++ 
 
++ 
 
8 
 
MG8 
 
++ 
 
++ 
 
9 
 
MG9 
 
++ 
 
++ 
 
where +++ indicates Very Clear solution, ++Clear solutions, + indicates 
Turbid solutions  
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9.3.2. Measurement of gelation temperature (T1):  
The physiological range of the nasal mucosal temperature lies 
between 32-34ºC. Pluronic F127 undergo thermal gelation or sol-gel 
transition at a temperature of about 25-37
 
ºC. 
The gelation temperature study shows  that loading of drug 
Rizatriptan Benzoate  and polymers like carboplol 974P and PEG 400 
alters the T1 of pluronic gel formulation that MG1,MG2, MG3 having 
gelation temperature of 27.53, 30.53, 28.53 having low level (0.25%) of 
carbopol whereas MG4,MG5, MG6 having gelation temperature of 
33.86, 36.73, 33.00 having middle level (0.5%) of carbopol where as 
MG7, MG8, MG9 having the gelation temperature of 37.93, 36.00, 38.53. 
It indicates that mucoadhesive polymer carbopol 974 P has increased T1 
whereas the addition of water soluble PEG 400 increased the T1. The 
phenomenon may be mediated through modification of miceller 
association of the PF 127 molecule. In addition the PEG molecules may 
form mixed micelles with PF127. The hydrophilic end chains of PF127 
the same PEO chains that are present in PEG. It is suggested that esters 
binds to these chains, promoting dehydration and causing an increase in 
entanglement of adjacent micelle. In the presence of PEG, association of 
Pluronic molecules were hindered and mixed miceller system with 
different physicochemical properties found.  
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9.3.3. Measurement of gel melting temperature (T2): 
The gel-sol effect depends on the addition of water soluble 
polymer PEG 400. The mucoadhesive polymer carbopol 974 P increases 
the T2 of the formulations. The gelmelting temperature of the 
formulations MG1,MG2, MG3 having 57.4, 50.6, 47.56 whereas MG4, 
MG5, MG6 having 44.00, 47.8, 53.13 where as MG7, MG8, MG9 having 
53.26, 53.26, 59.2. It indicates that addition of water soluble PEG 400 
produces increase in T1 while decrease in T2. 
The gelation temperature (T1) and gel melting temperature T2 of 
nine formulations of Rizatriptan Benzoate mucoadhesive nasal in situ 
gels were recorded in Table 9.11. 
  
 
 
  
 
 
 
 
 
250 
250 
250 
250 
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Table 9.11: Gelation Temperature (T1) and Gel Melting Temperature 
(T2) of Mucoadhesive Nasal In Situ Gels 
 
S.N0 
 
FORMULATION 
CODE 
 
GELATION 
TEMPERATURE 
(T1°C) ± SD 
 
 
GEL MELTING 
TEMPERATURE 
(T2°C) ± SD 
 
1 
 
MG1 
 
27.53±0.94 
 
 
57.40±1.03 
 
2 
 
MG2 
 
30.53±1.66 
 
 
50.60±1.01 
 
3 
 
MG3 
 
28.53±1.13 
 
 
47.56±1.35 
 
4 
 
MG4 
 
 
33.86±0.30 
 
44.00±0.52 
 
5 
 
MG5 
 
36.73±0.30 
 
 
47.80±1.38 
 
6 
 
MG6 
 
33.00±1.38 
 
 
53.13±1.44 
 
7 
 
MG7 
 
37.93±0.46 
 
 
53.26±1.17 
 
8 
 
MG8 
 
36.00±0.34 
 
 
53.26±1.33 
 
9 
 
 
MG9 
 
 
38.53±1.15 
 
 
59.20±0.91 
                      
                        All the values are expressed as mean± S.D., n=3. 
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Fig. 9.12: Comparison of Gelation Temperature (T1) and Gel Melting 
Temperature (T2) 
 Fig.9.13: Quadric 3D surface plot showing the effect of Carbopol 974P 
and PEG 400 on Gelation temperature (T1) 
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The above figure (9.13) indicates, that the mucoadhesive polymer use i.e. 
Carbopol 974P has significant T1 (gelation temperature) lowering effect. 
Also the addition of water soluble polymer PEG 400 produces increase in 
T1. 
9.3.3. Determination of pH: 
The pH of nine formulations of Rizatriptan Benzoate mucoadhesive nasal 
in situ gels were recorded in Table 9.12. 
                 Table 9.12: pH of Mucoadhesive Nasal In Situ Gels 
S.NO FORMULATION 
CODE 
pH ±S.D.  
1 MG1 6.17±0.06  
2 MG2 5.70±0.28 
3 MG3 6.22±0.02 
4 MG4 6.40±0.02 
5 MG5 6.51±0.09 
6 MG6 6.28±0.21 
7 MG7 6.51±0.08 
8 MG8 6.78±0.12 
9 MG9 5.98±0.01 
 
                 All the values are expressed as mean± S.D., n=3. 
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Fig. 9.14: Comparison of pH of all Formulations 
It is known that the normal physiological pH  of nasal mucosa is 
4.5-6.5. However the nasal mucosa can tolerate solutions within pH range 
of 3-10. pH of all the nine formulations were found to be within 5.70-
6.78 that is between physiological range of pH of nasal mucosa. 
9.3.4. Determination of Drug Content:  
The drug content of nine formulations of  Rizatriptan Benzoate 
mucoadhesive nasal in situ gels were recorded in Table 9.13. 
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  Table 9.13: Drug Content of Mucoadhesive Nasal In Situ Gels 
 
S.NO 
 
FORMULATION CODE 
 
    DRUG CONTENT±S.D. 
(%)  
 
1 
 
 
MG1 
 
85.60±0.27 
 
2 
 
 
MG2 
 
87.64±0.43 
 
3 
 
 
MG3 
 
83.23±0.27 
 
4 
 
 
MG4 
 
98.97±0.16 
 
5 
 
 
MG5 
 
97.11±0.27 
 
6 
 
 
MG6 
 
96.56±0.26 
 
7 
 
 
MG7 
 
92.42±0.99 
 
8 
 
 
MG8 
 
88.52±0.33 
 
9 
 
 
MG9 
 
90.92±0.21 
                                    
                              All the values are expressed as mean± S.D., n=3. 
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                                          Fig. 9.15: Comparison of Drug Content 
The percentage drug content of all the prepared in situ gels 
formulations swere checked and found to be in the range of 83.23-
98.97%. 
9.3.5. Measurement of Mucoadhesive Strength:  
The measurement of mucoadhesive strength of nine formulations 
of Rizatriptan Benzoate mucoadhesive nasal in situ gels were recorded in 
Table 9.14. 
Mucoadhesive strength increases with increasing the 
concentration of mucoadhesive polymer. 
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Results of mucoadhesive strength indicates that the variable 
carbopol 974P and PEG 400 both are having the effect on mucoadhesive 
strength. 
Table 9.14:  Mucoadhesive Strength of Mucoadhesive Nasal In situ Gels 
 
S.NO 
 
FORMULATION 
CODE 
 
MUCOADHESIVE 
STRENGHT* 
(g)±S.D. 
 
MUCOADHESIVE 
STRENGHT* 
(d/cm²)±S.D. 
 
1 
 
MG1 
 
22.66±1.15 
 
11056.90±0.23 
 
2 
 
MG2 
 
25.33±1.52 
 
11869.91±0.25 
 
3 
 
MG3 
 
24.66±0.57 
 
12032.52±0.31 
 
4 
 
MG4 
 
31.66±1.52 
 
15447.15±1.50 
 
5 
 
MG5 
 
37.00±1.00 
 
18687.80±0.15 
 
6 
 
MG6 
 
41.66±1.52 
 
20325.21±0.72 
 
7 
 
MG7 
 
51.00±1.00 
 
25040.65±0.73 
 
8 
 
MG8 
 
54.00±1.73 
 
27674.37±0.66 
 
9 
 
MG9 
 
57.33±0.57 
 
27967.47±0.99 
                           
                                     All the values were expressed as mean S.D., n*=3 
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                      9.16: Comparison of  Mucoadhesive Strength in gm 
 
                 Fig. 9.17: Comparison of Mucoadhesive Strength in d/cm² 
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Fig.9.18: Quadric 3D surface plot showing the effect of Carbopol    974P 
and PEG 400 on Mucoadhesive strength 
           Mucoadhesive strength increases with increasing concentration of mucoadhesive 
polymer. 
           Determination of mucoadhesive strength  in terms of detachment stress showed that 
adhesive property increases with addition of  Carbopol 974P. The stronger the 
mucoadhesive strength is, the more it can prevent the gelled solution coming out of the 
nose. But if the bioadhesive strength is too excessive, the gel can damage the nasal mucosal 
membrane.  
9.3.6. Measurement of Vicostiy:   The measurement of of nine formulations of Rizatriptan 
Benzoate mucoadhesive nasal in situ gels were recorded in Table 9.15. 
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           Table 9.15: Viscosity of Mucoadhesive Nasal In Situ Gels 
   
                    All the values are expressed as mean± S.D., n=3. 
 
TEMPERATURE 
°C 
 
                                       VISCOSITY MEASUREMENTS (cPs)±S.D. 
 
                                                   Formulation code 
 
MG1 
 
MG2 
 
MG3 
 
MG4 
 
MG5 
 
MG6 
 
MG7 
 
MG8 
 
MG9 
 
20 °C 
 
830.00 
 
±1.00 
 
727.33 
 
±1.52 
 
841.33 
 
±1.55 
 
965.00 
 
±1.00 
 
992.00 
 
±1.00 
 
1022.66 
 
±1.52 
 
1093.33 
 
±0.57 
 
1247.00 
 
±1.00 
 
1205.66 
 
±1.15 
 
22 °C 
 
840.00 
 
±1.52 
 
780.00 
 
±1.00 
 
871.33 
 
±1.52 
 
981.00 
 
±1.00 
 
1018.0 
 
0±1.00 
 
1114.33 
 
±0.57 
 
1012.66 
 
±1.52 
 
1372.33 
 
±1.52 
 
1571.66 
 
±0.57 
 
24 °C 
 
861.66 
 
±1.52 
 
793.00 
 
±0.57 
 
893.00 
 
±1.00 
 
1021.6 
 
6±0.57 
 
1126.3 
 
3±1.52 
 
1374.00 
 
±1.73 
 
1231.00 
 
±1.73 
 
1755.00 
 
±1.00 
 
1922.33 
 
±1.52 
 
26 °C 
 
921.66 
 
±1.52 
 
824.00 
 
±0.57 
 
930.66 
 
±1.52 
 
1072.6 
 
6±0.57 
 
1573.0 
 
0±1.00 
 
1731.00 
 
±1.00 
 
1599.33 
 
±1.52 
 
2002.33 
 
±1.52 
 
2210.00 
 
±1.00 
 
28 °C 
 
1080.6 
 
6±1.15 
 
851.33 
 
±1.52 
 
970.66 
 
±1.52 
 
1160.6 
 
6±1.52 
 
1961.6 
 
6±1.52 
 
2142.00 
 
±1.73 
 
1975.00 
 
±1.00 
 
2242.33 
 
±1.52 
 
2692.00 
 
±1.00 
 
30 °C 
 
1120.6 
 
6±1.15 
 
942.00 
 
±1.00 
 
1160.6 
 
6±1.15 
 
1861.0 
 
0±1.00 
 
2262.0 
 
0±1.73 
 
2670.33 
 
±1.52 
 
2273.00 
 
±1.00 
 
2791.66 
 
±1.52 
 
3097.66 
 
±1.15 
 
32  °C 
 
1185.0 
 
0±1.00 
 
1121.0 
 
0±0.57 
 
1251.6 
 
6±1.50 
 
2226.6 
 
6±0.57 
 
2591.0 
 
0±1.00 
 
2996.00 
 
±1.00 
 
3001.33 
 
±1.52 
 
3143.33 
 
±1.52 
 
3211.33 
 
±1.15 
 
34 °C 
 
1200.6 
 
6±1.52 
 
1260.3 
 
3±1.00 
 
1337.0 
 
0±1.73 
 
2699.0 
 
0±1.00 
 
2780.6 
 
6±1.52 
 
3030.66 
 
±1.52 
 
3247.00 
 
±1.00 
 
3248.00 
 
±1.00 
 
3481.00 
 
±1.00 
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                     Fig. 9.19: Comparison of Viscosity of MG1-MG9 formulation. 
 
Fig.9.20: Quadric 3D surface plot showing the effect of Carbopol 974P and PEG 400 
on viscosity 
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The figure (9.20) shows the viscosity profile of formulations at 34ºC. It shows 
that mucoadhesive polymer carbopol 974P had a viscosity enhancing effect. On the 
other hand, PEG polymer counteracted the viscosity enhancing effect caused by 
carbopol 974P.  
           Viscosity measurement of the nine formulations at various temperatures shows 
that there was increase in viscosity with increase in temperature. This indicates the 
temperature induced gel structure formation of pluronic F127. 
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9.3.7. In-vitro drug permeation studies: 
 Table 9.16: In-vitro drug permeation profile of formulation  MG1, MG2, 
MG3. 
   
S.No. Time 
in 
hours 
Medium MG1 
(%) 
MG2 
(%) 
MG3 
(%) 
1 1  
pH 6.4 
 
P 
H 
O 
S 
P 
H 
A 
T 
E 
 
B 
U 
F 
F 
E 
R 
 
 
0.00 0.00 0.00 
2 2 5.29 ± 
 0.15 
8.00 ± 
 0.13 
6.40 ± 
 0.13 
3 3 9.32 ± 
 0.20 
12.05± 
0.13 
07.66 ± 
0.31 
4 4 13.15 ± 
0.16 
19.32± 
0.13 
12.87 ± 
0.65 
5 5 21.03± 
0.09 
27.26± 
0.13 
16.79 ± 
0.39 
6 6 37.03± 
0.15 
36.95± 
0.13 
22.94 ± 
0.39 
7 7 52.66± 
0.50 
47.26 ± 
68.05 
25.81 ± 
1.41 
8 8 70.40± 
0.13 
68.05± 
0.14 
28.48 ± 
0.87 
9 9 85.27± 
0.16 
87.34± 
0.14 
82.06± 
0.16 
                          
All the values are expressed as mean± S.D., n=3. 
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Table 9.17: In-vitro drug permeation profile of formulation MG4, MG5, 
MG6. 
 
S.No. Time 
in 
hours 
Medium MG4 
(%) 
MG5 
(%) 
MG6 
(%) 
1 1  
      pH 6.4 
 
P 
H 
O 
S 
P 
H 
A 
T 
E 
 
B 
U 
F 
F 
E 
R 
 
 
0.00 0.00 0.00 
2 2 17.86 ± 
0.13 
18.57 ± 
0.15 
17.86±  
0.13 
3 3 23.38± 
0.14 
20.56± 
0.21 
21.11 ± 
0.13 
4 4 31.93± 
0.20 
26.86± 
0.15 
25.79 ± 
0.13 
5 5 36.43± 
0.13 
33.08± 
0.15 
32.41±  
0.15 
6 6 45.28± 
0.20 
49.40 ± 
0.23 
48.18 ± 
0.20 
7 7 68.83± 
0.16 
71.36± 
0.17 
67.59±  
0.14 
8 8 75.97± 
0.16 
82.65± 
0.22 
81.94±  
0.14 
9 9 98.04± 
0.15 
96.56± 
0.16 
96.06 ± 
0.19 
 
All the values are expressed as mean± S.D., n=3. 
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Table 9.18: In-vitro drug permeation profile of formulation MG7, MG8, 
MG9. 
S.No. Time 
in 
hours 
Medium MG7 
(%) 
MG8 
(%) 
MG9 
(%) 
1 1  
pH 6.4 
 
P 
H 
O 
S 
P 
H 
A 
T 
E 
 
B 
U 
F 
F 
E 
R 
 
 
0.00 0.00 0.00 
  
2 2 17.95 ± 
0.20 
18.80 ± 
0.40 
18.00±  
0.27 
3 3 20.98± 
0.27 
20.93± 
0.26 
21.96 ± 
0.27 
4 4 25.88± 
0.19 
22.93± 
0.34 
25.54± 
 0.41 
5 5 35.74± 
0.22 
30.54± 
0.55 
33.15 ± 
0.25 
6 6 52.31± 
0.23 
46.60± 
0.62 
51.44±  
0.26 
7 7 67.17± 
0.43 
62.31± 
0.15 
65.25± 
 0.15 
8 8 80.20± 
0.10 
74.33± 
0.50 
78.26 ± 
0.27 
9 9 52.95 ± 
0.86 
88.24± 
0.02 
90.49± 
 0.20 
 
All the values are expressed as mean± S.D., n=3. 
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                Fig. 9.21: In-vitro drug permeation profile of formulation MG1         
 
                Fig. 9.22: In-vitro drug permeation profile of formulation MG2 
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                Fig. 9.23: In-vitro drug permeation profile of formulation MG3        
 
     Fig. 9.24: In-vitro drug permeation profile of formulation MG4 
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                Fig. 9.25: In-vitro drug permeation profile of formulation MG5     
 
         Fig. 9.26: In-vitro drug permeation profile of formulation MG6 
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              Fig. 9.27: In-vitro drug permeation profile of formulation MG7 
      
 
                 Fig. 9.28: In-vitro drug release permeation of formulation MG8 
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                Fig. 9.29: In-vitro drug permeation profile of formulation MG9 
         Fig. 9.30: Comparative in-vitro drug permeation of all formulations 
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In-vitro diffusion studies revealed that the release of Riztriptan 
Benzoate from different formulations varies with the characteristics and 
composition of polymers as shown in Figures 9.21 to 9.30. 
The formulated mucoadhesive in situ gels showed a most 
favorable release within 5 hours.  In the 5
th 
hour, the drug permeation was 
85.27%, 87.34%, 82.06%, 98.09, 96.56, 92.32, 88.24, 90.49 and 97.17% 
for MG1, MG2, MG3, MG4, MG5, MG6, MG7, MG8 and MG9 
respectively. This was followed by a steady drug release pattern.  
 
From these above data, it showed formulation MG4 permeated 
drug mostly at the end of 5 hours. The in-vitro drug permeation rate of 
Rizatriptan Benzoate shows that with increasing carbopol 974P 
concentration influences the diffusion of drug particle while addition of 
PEG 400 enhances the drug permeation. 
 
  Among all the nine formulations, formulation MG4 (composed 
of Rizatriptan Benzoate 1%w/v, 18% w/v PF 127, 0.5% w/v carbopol 
974P, 6% w/v PEG 400) exhibited the highest in-vitro drug permeation of 
98.09 at 5 hours, while the lowest drug release of 82.06 was recorded for 
formulation containing (composed of Rizatriptan Benzoate 1%w/v, 18% 
w/v PF 127, 0.25% w/v carbopol 974P, 10% w/v PEG 400).   
 
From the above evaluation parameters it was concluded that the   
Formulation MG4 having a maximum percentage of drug release in a 
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controlled manner, so the formulation MG4 was selected as the optimized 
formulation. 
9.3.8. Histopathological study of optimized formulation: 
 The histopathological study were determined by using sheep 
nasal mucosa. The histological report of both control and optimized 
formulation were showed in Figure 9.31 and 9.32 
  
 
                                
 
 
 
 
 
 
 
 
 
 
Fig. 9.31: Histopathology of nasal mucosa Control 
Nasal In situ Gel of Rizatriptan Benzoate   Results and Discussion 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 145 
            
Fig. 9.32: Histopathology of nasal mucosa Optimized Nasal In Situ Gel 
formulation. 
Photomicrographs of nasal mucosa after the permeation studies 
were observed for histopathological study with the phosphate buffer 6.4 
treated mucosa. 
The section of mucosa treated with optimized formulation MG4 
showed no degeneration of nasal epithelium along with no signs of 
erotion.  
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9.3.9. Kinetics of In-vitro drug permeation:
 
 
                The kinetics of in-vitro drug permeation was determined by 
applying the drug release data to various kinetic models such as zero 
order, first order, Higuchi and Korsmeyer- Peppas. The result obtained 
was shown in Table 9.19.  
          Table 9.19: Different kinetic models for Rizatriptan Benzoate 
Nasal In Situ Gels (MG1 to MG9) 
 
S.
N
O 
F. 
Code 
Zero 
order 
First 
order 
Higuc
hi 
Korsemeyer- 
Peppas Best fit 
model 
R
2
 R
2
 R
2
 R
2
 n 
1 MG1 0.9602 0.9608 0.9825 0.9915 0.5992 Peppas 
2 MG2 0.9249 0.9258 0.9834 0.9878 0.5248 Peppas 
3 MG3 0.9394 0.9401 0.9860 0.9892 0.5579 Peppas 
4 MG4 0.8382 0.8400 0.9897 0.9865 0.5996 Higuchi 
5 MG5 0.8743 0.8758 0.9956 0.9865 0.4596 Higuchi 
6 MG6 0.8788 0.8758 0.9956 0.9837 0.4596 Higuchi 
7 MG7 0.8432 0.8448 0.9973 0.9890 0.4505 Higuchi 
8 MG8 0.8493 0.8509 0.9938 0.9769 0.4287 Higuchi 
9 MG9 0.8459 0.8476 0.9966 0.9864 0.4417 Higuchi 
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               Fig. 9.33: Best fit kinetic release of formulation MG1 
              
                Fig. 9.34: Best fit kinetic release of formulation MG2 
            
                 Fig. 9.35: Best fit kinetic release of formulation MG3 
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           Fig. 9.36: Best fit kinetic release of formulation MG4 
             
                 Fig. 9.37: Best fit kinetic release of formulation MG5 
           
          Fig. 9.38: Best fit kinetic release of formulation MG6 
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                 Fig. 9.39: Best fit kinetic release of formulation MG7 
            
               Fig. 9.40: Best fit kinetic release of formulation MG8 
             
                 Fig. 9.41: Best fit kinetic release of formulation MG9 
 
Nasal In situ Gel of Rizatriptan Benzoate   Results and Discussion 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 150 
 9.3.10: Stability studies: 
            After exposure to  stability conditions (40ºC ±2ºC at 75% RH 
±5% RH) the formulation was analyzed for various evaluation 
parameters; results are shown in Table 9.20-9.21. 
              Table 9.20: Stability studies of optimized formulation MG4  
Characteristic Initials 1
st
 Month 2
nd
 Month 3
rd
 Month 
Clarity +++ 
 
+++ 
 
+++ 
 
+++ 
 
Gelation 
Temperature 
(T1) 
33.86± 
0.30 
33.66± 
0.30 
33.50± 
0.36 
 
33.33± 
0.41 
 
Gel Melting 
Temperature 
(T2) 
44.000.52 
 
42.76±1.42 41.86±1.61 40.96±0.25 
pH 6.40±0.02 6.38 ±0.05 6.53 ±0.02 6.21± 0.02 
 
Drug Content 98.97±0.16 98.47±0.11 98.25±0.14 97.92±0.17 
 
Invitro Drug 
Permeation at 5 h 
(%) 
98.09± 
0.15 
97.61±0.15 97.44±0.14 97.03±0.08 
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Fig. 9.42: Comparison of gelation ans ge lmelting temperature   before 
and after stability studies at 40°C ±2°C at 75% RH ± 5% for optimized 
formulation MG4 
 
Fig. 9.43: Comparison of pH before and after stability studies at                                              
40°C ±2°C at 75% RH ± 5% for optimized formulation MG4 
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Fig. 9.44: Comparison of drug content of selected formulation MG4 after 
stability studies at 40°C ±2°C at 75% RH ± 5% 
Table 9.21: Percentage in-vitro drug permeation of selected formulation 
MG4 after stability studies at 40°C ±2°C at 75% RH ± 5%. 
 
                           All the values were expressed as mean S.D., n*=3 
 
S. No 
 
Time  in 
mins 
40°C ±2°C at 75% RH ± 5% 
Initial*  1
st
 month* 2
nd
 month* 3
rd
 month* 
1 1 17.86±0.13 17.20±0.13 16.93±0.13 16.80±0.13 
2 2 23.38±0.14 22.82±0.14 22.63±0.08 22.31±0.07 
3 3 31.93±0.20 31.83±0.14 31.73±0.08 31.44±0.08 
4 4 36.43±0.13 36.07±0.08 35.96±0.14 35.66±0.13 
5 5 45.28±0.20 45.08±0.19 45.01±0.24 44.84±0.13 
6 6 68.83±0.16 68.41±0.27 68.29±0.14 68.02±0.08 
7 7 75.97±0.16 75.80±0.20 75.68±0.12 75.49±0.13 
8 8 98.09±0.15 97.61±0.15 97.44±0.14 97.03±0.08 
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 Fig. 9.45: Percentage in-vitro drug permeation of selected formulation 
MG4 after stability studies at 40°C ±2°C at 75% RH ± 5% 
 
 
 Fig. 9.46: Comparison of in- vitro drug permeation before and after 
stability studies at 40°C ±2°C at 75% RH ± 5% for optimized formulation 
MG4 
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The studies revealed that, there were no much significant changes 
in was intimate between the evaluated data from initial after stability 
studies of Clarity, pH, Gelation temperature (T1) and gel melting 
temperature (T2), drug content and in-vitro drug permeation studies and 
all the values were found in worth accepting limits after the stability 
studies at 40°C ±2°C at 75% RH ± 5% for optimized formulation MG4. 
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10. SUMMARY AND CONCLUSION 
 
The present study was aimed to develop a mucoadhesive nasal in situ gel 
delivery system for the treatment of antimigraine activity. Nine batches of 
mucoadhesive nasal in situ gels (MG1, MG2, MG3, MG4, MG5, MG6, MG7, MG8, 
and MG9) were prepared by using carbopol 974P, PEG 400 and drug with 3
2 
factorial 
design by Cold method.  
Preformulation study was carried out for crude drug. The initial part of work 
was started from the identification of drug. Identification of drug was determined by 
melting point and solubility.  
The compatibility studies by FTIR and DSC analysis of in situ gels suggest 
that the drug Rizatriptan Benzoate with polymers like carbopol 974P, PEG 400 and  
thermoreversible polymer Pluronic F 127 do not interact to form any additional 
chemical entity but remain as a mixture. Therefore, it could indicate that there was no 
incompatibility between drug and polymers. The similarity in peaks indicates there is 
no incompatibility between drug and the polymers.  
The measurement of gelation temperature (T1) and gel melting temperature 
(T2) were found to be in the considerable range and it showed that addition of 
mucoadhesive polymer carbopol 974P has decreased T1 whereas addition of PEG 400 
increased T1. 
pH of the all formulations were found to be within 5.7-6.78 that is between 
physiological range of pH of nasal mucosa. 
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The percentage drug content of all the prepared in situ gel formulations were 
checked and found to be in the range of 83.23-98.97%. 
Mucoadhesive strength increases with increasing concentration of 
mucoadhesive polymer. The results of prepared mucoadhesive nasal in situ gels 
indicates that the independent variables carbopol 974P (X1) and PEG 400 (X2) both 
are having the effect of mucoadhesive strength. 
Viscosity measurement of the formulations at various temperatures shows that 
there was increase in viscosity with increase in temperature. This indicates that 
temperature induced gel structure formation of pluronic F 127. 
   From in-vitro permeation studies  it was concluded that formulation MG4 
(composed of Rizatriptan Benzoate 1%w/v, 18% w/v PF 127, 0.5% w/v carbopol 
974P, 6% w/v PEG 400) found to be best formulation among other formulations, 
which showing the most desired drug permeation. It will be considered as optimized 
formulation. 
 
The optimized formulation MG4 was subjected to histopathological and 
stability studies. The photographs of nasal mucosa after the permeation studies were 
observed for histopathological study. The section of mucosa treated with optimized 
formulation showed no degeneration of nasal epithelium along with no signs of 
erosion. 
 
The studies revealed that, there were no much significant changes in 
percentage clarity, gelation temperature and gel melting temperature, pH, drug 
content and in-vitro drug permeation studies for three months at 40ºC.  
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Out of the nine formulations, it appears that Formulation MG4 has the 
maximum potential in providing In situ gel nasal delivery system. This formulation 
was considered as best formulation for temperature induced nasal in situ gelling 
system for the treatment of anti-migraine activity with respect to its evaluation 
parameters like clarity, gelation temperature and gel melting temperature, pH, drug 
content and in-vitro drug release and this formulation may give patient friendly and 
needle free dosage form. 
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11. FUTURE PROSPECTS 
 
In the present work the Temperature induced mucoadhesive nasal in situ gel of 
Rizatriptan Benzoate were prepared by using carbopol 974P and PEG 400 and with 3
2
 
factorial design by cold method. In this investigation, the important parameters like 
physico chemical characterization, in-vitro evaluation, histopahhological studiest of 
mucoadhesive nasal in situ gelling system of Rizatriptan benzoate were done. Further 
detailed investigation and elaborate in-vivo studies using human volunteers need to be 
carried out to establish efficacy of this formulation.  
In order to have a comparative evaluation of in-vivo performance such as 
pharmacokinetic analysis will be performed on plasma concentration time profiles of 
this formulation after nasal route of administration, since plasma profile is an 
important aspect in understanding biological action of a drug. In-vitro/In-vivo 
correlation studies to be performed in future. 
In future the long term stability studies will be required to know the shelflife 
of the prepared muoadhesive nasal in situ gels.  
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